AOP ID and Title:
Graphical Representation
Status
| Author status | OECD status | OECD project | SAAOP status |
|---|---|---|---|
| Under development: Not open for comment. Do not cite | Under Development | 1.97 | Included in OECD Work Plan |
Abstract
This AOP links inhibition of ALDH1A during fetal life with female infertility in adulthood. A key step in this AOP is a reduction in all-trans retinoic acid (atRA) locally in the fetal ovary, which prevents resident germ cells (oocytes) from entering meiosis. Evidence for this AOP, especially upstream events, draws heavily from mouse studies, both genetic models and from exposure studies (including explanted ovaries). Human evidence is also available, especially for downstream events where the oocyte pool/ovarian reserve is known to directly impact on fertility. In reproductive toxicity (animal studies and human epidemiology) fertility is an apical endpoint of high importance and has strong utility for chemical safety assessments. Infertility can be caused by many, and varied, factors, but this AOP focusses on linking perturbed meiosis through disrupted atRA signaling during development, thus supporting the use of data from in silico and in vitro measurements for interference with nuclear receptor activity (RAR/RXR) and atRA synthesis/expression to infer potential to cause in vivo effects.
Background
In mammals, the primordial germ cells are initially ‘bipotential’. They will develop into either oocytes or gonocytes in ovaries or testis, respectively, depending on cues from the somatic environment. Germ cells in the developing testis will enter a quiescent state and reactivate at the onset of puberty. In contrast, germ cells in the developing ovary will enter meiosis (prophase I) during fetal life. A key signaling event for this sexual dimorphic germ cell programming is retinoid signaling, with all-trans retinoic acid (atRA) acting as a meiosis-inducing factor (Spiller & Bowles, 2019).
The source of atRA during ovary development differs to some degree between species. In mice, the adjacent mesonephros, which expresses two enzymes necessary for the final step in atRA production, ALDH1A2 and ALDH1A3, is likely the main source of atRA at early developmental stages (Bowles et al, 2018; Bowles et al, 2006; Koubova et al, 2006; Niederreither et al, 1999). There is also the capacity for atRA to be produced within the ovary itself, due to local expression of the atRA-synthesizing enzyme ALDH1A1 (Bowles et al, 2016; Mu et al, 2013).
In humans, ALDH1A enzymes (ALDH1A, -1B and -1C) are expressed in both testes and ovaries of the developing fetus, which suggest a capacity for de novo synthesis of atRA (Childs et al, 2011; Jørgensen & Rajpert-De Meyts, 2014; le Bouffant et al, 2010), as is also the case in rabbits (Díaz-Hernández et al, 2019). One team studying human fetal ovaries reported a peak of ALDH1A1 expression at the onset of meiosis (le Bouffant et al, 2010), suggesting that meiotic onset in the human ovary depends on provision of atRA at the correct time. There seems to be conservation from rodent to human in terms of the requirement for atRA to induce the pre-meiotic factor STRA8. However, in mice atRA is produced by adjacent tissue and is present at high concentrations in the ovaries, whereas in human ovaries RA is present at only low levels and is then actively produced to induce meiosis in the ovary (Spiller & Bowles, 2019).
Summary of the AOP
Events
Molecular Initiating Events (MIE), Key Events (KE), Adverse Outcomes (AO)
| Sequence | Type | Event ID | Title | Short name |
|---|---|---|---|---|
| 1 | MIE | 1880 | Inhibition of ALDH1A (RALDH) | ALDH1A (RALDH), inhibition |
| 2 | KE | 1881 | Decreased, all-trans retinoic acid (atRA) concentration | Decreased, atRA concentration |
| 3 | KE | 1882 | Disrupted meiotic initiation of fetal oogonia of the ovary | Oocyte meiosis, disrupted |
| 4 | KE | 1883 | Reduced size of the ovarian follicle pool | Ovarian follicle pool, reduced |
| 5 | KE | 405 | irregularities, ovarian cycle | irregularities, ovarian cycle |
| 6 | AO | 406 | impaired, Fertility | impaired, Fertility |
Key Event Relationships
| Upstream Event | Relationship Type | Downstream Event | Evidence | Quantitative Understanding |
|---|---|---|---|---|
| Inhibition of ALDH1A (RALDH) | adjacent | Decreased, all-trans retinoic acid (atRA) concentration | High | Moderate |
| Decreased, all-trans retinoic acid (atRA) concentration | adjacent | Disrupted meiotic initiation of fetal oogonia of the ovary | Moderate | Low |
| Disrupted meiotic initiation of fetal oogonia of the ovary | adjacent | Reduced size of the ovarian follicle pool | High | Moderate |
| Reduced size of the ovarian follicle pool | adjacent | irregularities, ovarian cycle | Moderate | Low |
| irregularities, ovarian cycle | adjacent | impaired, Fertility | High | Low |
Overall Assessment of the AOP
The majority of evidence supporting this AOP is derived from mouse studies, both in vitro (fetal ovary cultures) and in vivo (incl. genetic mouse models). There is also evidence from humans (in vitro ovary cultures), yet it is also recognized that there are some differences between mice and humans with regard to atRA synthesis, expression and potential role in meiotic initiation. Notably, an important link, yet not described as a separate key event, is the role for Stra8 in meiotic initiation alongside the established role for atRA to control Stra8 expression via RAR/RXR.
The evidence linking MIE with KE1 is considered as strong and regarded as canonical knowledge. Likewise, evidence for the downstream key events linking reduced oocyte pool/ovarian reserve with reduced fertility is very strong and regarded as canonical knowledge. The weak link in the overall AOP is the connection between reduced atRA levels and fertility via loss of oocytes during development. To strengthen this link, more evidence must be obtained; nevertheless, the remaining links are very strong and can be used to assess the impact of chemical stressors on female fertility. Yet, caution should be exercised with directly linking inhibition of ALDH1A2 with reduced fertility.
Domain of Applicability
Life Stage Applicability| Life Stage | Evidence |
|---|---|
| During development and at adulthood | High |
| Term | Scientific Term | Evidence | Links |
|---|---|---|---|
| mouse | Mus musculus | High | NCBI |
| rat | Rattus norvegicus | Moderate | NCBI |
| human | Homo sapiens | Moderate | NCBI |
| Sex | Evidence |
|---|---|
| Female | High |
-
Sex: This AOP applies to females. atRA is also involved in meiosis of testicular gonocytes, but this occurs postnatally. In the female ovaries, atRA induces meiosis of oocytes during gestation, thus the spatiotemporal expression of atRA in the ovaries are tightly controlled. Finally, as this AOP is concerned with establishing the ovarian reserve/follicle pool through mechanisms that are unique to ovaries, restricting the AOP to female only is appropriate.
-
Life stages: This AOP spans the period from mid- to late-gestation in mammals, all the way to adulthood where fertility is manifested. The upstream event pertains to fetal/neonatal life stages, whereas the downstream events pertain to adult reproductive life stages.
-
Taxonomy: Strongest evidence for the role of atRA in regulating oocyte entry into meiosis stems from mouse studies, so the taxonomic applicability is strongest for this animal model. Studies have also been done in rats. Evidence for the same mechanisms in humans is less substantiated (Li & Clagett-Dame, 2009; Griswold et al, 2012; Spiller & Bowles, 2022; Jørgensen & Rajpert-De Meyts, 2014).
Essentiality of the Key Events
The critical first stage of this AOP is the lack of atRA in ovaries at the stage where oocytes need to enter meiosis during gestation. Failure to enter meiosis at the correct time during development is detrimental to oocyte development and ultimately this will compromise the follicle pool in adulthood; a non-renewable source for producing viable eggs for fertilization. However, reduced atRA is not defined as the MIE in this AOP, as atRA synthesis by the action of ALDH1A enzymes is required, and this synthesis step is a potential vulnerable point for chemical perturbation.
- MIE (Inhibition, ALDH1A): atRA is synthesized from dietary vitamin A in a two-step enzymatic process, where ALDH1A is responsible for the second, irreversible oxidation of retinal to atRA (Chatzi et al, 2013; Shannon et al, 2017).
- KE1 (Decreased atRA): Although ALDH1A enzymes can make different retinoid metabolites (9-cis, 13-cis, all-trans), atRA is considered the only active metabolite in mammals (Krężel et al, 2019). atRA acts locally in tissues as a paracrine, short-range, signaling molecule (Teletin et al, 2017). In the mouse, atRA is synthesized in the adjacent mesonephros and diffuses into the gonad proper to establish local concentrations required for organogenesis (Chassot et al, 2020; Kumar et al, 2011), including prompting oocytes to enter meiosis (Bowles et al, 2006; Koubova et al, 2006). In humans, atRA appears to be synthesized locally in the ovary. This KE is essential for this AOP as represents the essential link between ALDH1A inhibition by chemicals with reduced fertility in adult females.
- KE2 (disrupted meiosis): The downstream KE of this AOP, reduced follicle pool, can arise from multiple events, of which disrupted meiosis is only one. Nevertheless, disrupted meiosis is essential for this AOP in that it is the clear rational link between inhibited retinoid signaling and reduced fertility via diminished ovarian reserve. For meiosis to initiate in the mouse, oocytes need to express Stra8 (Baltus et al, 2006), a factor that is regulated by atRA via retinoid receptors RAR/RXR (Bowles et al, 2016; Bowles et al, 2006; Feng et al, 2021; Koubova et al, 2006). Although the role for atRA for initiating meiosis in humans is still under some debate, the role for Stra8 appears essential also for human oocytes to initiate meiosis (Childs et al, 2011).
- KE3 (reduced ovarian reserve): In mammals, it is broadly accepted that females are born with a set number of follicles, termed the ovarian reserve, which is dependent on proper development, including meiotic initiation, during fetal life (Grive & Freiman, 2015). A large number of oocytes are lost during ovarian/oocyte development to ensure a quality ovarian reserve. However, a minimum amount of oocytes are required to establish and maintain adult reproductive function. Therefore this KE represents an essential step in the AOP, since falling below a critical number of follicles will lead to disrupted ovary function and irregular cyclicity (as normally occurs during menopause).
- KE4 (irregular ovarian cycle): Female fertility depends on the ovarian cycle to produce competent follicles for ovulation and fertilization. Thus, this KE is an essential step in determining fertility status.
- AO impaired fertility, female: Fertility represents the capability to reproduce and as such is the essential AO of this AOP. It is measurable both at the individual and population level. Although the AO of this AOP (ID 406) describe impaired fertility independent of sex, the AOP is specific to females as it involves oocyte/ovary development and function.
Weight of Evidence Summary
Biological Plausibility, coherence, and consistency of the experimental evidence
The role for ALDH1A2 in the synthesis of atRA is well established as an essential component of regulating regional expression of retinoid species during development. It is also well established that atRA is an inducer of meiosis in germ cells in mice; however, there is some debate about the essentiality of atRA in this process in human fetal ovaries. The requirement for oocytes to enter the first phase of meiosis during fetal development is also well established, hence the biological plausibility linking meiotic failure with loss of oocytes at later developmental stages is strong.
Although non-meiotic oocytes can survive in germ cell nests and during nest breakdown, they will ultimately be eliminated from the oocyte pool of competent follicles. There is therefore a direct link between meiotic entry and fertility during adulthood. Thus, this AOP provides a plausible chain of events linking reduced atRA during fetal life with reduced ovarian reserve and fertility during reproductive age. The strength of the downstream KEs and KER – reduced ovarian reserve and reduced fertility – is very well documented and thus the biological plausibility is very strong. Evidence for a direct link between the AO and perturbed atRA synthesis, or reduced atRA levels, during early development comes mainly from mouse studies; yet the relationship is regarded biologically plausible also in humans, but with weight of evidence not being as strong.
Concordance of dose-response relationships
The quantitative understanding of dose-response relationships in this AOP is limited. Whilst the relative levels of endogenous atRA produced by the ovary (for any species) remains unknown, similarly, the quantitative relationship between atRA levels and induction of meiosis also remains unclear. Nevertheless, it is has been conclusively shown that low levels of exogenous atRA can induce mouse and rat germ cells to enter meiosis both in vitro and ex vivo (Bowles et al, 2006; Livera et al, 2000). Likewise, atRA is necessary to achieve meiosis in in vitro-derived oocytes via PGCLCs (Miyauchi et al, 2017).
Temporal concordance among the key events and the adverse outcome
This AOP bridges two different life stages: fetal/perinatal and adult/reproductive age. The adverse outcome is the result of perturbation taking place during early stages of ovary development. In mice, rats and humans, the oocytes must enter meiosis prophase in order to establish the follicle pool/ovarian reserve postnatally. Thus, the AOP focusses on chemical perturbations during fetal life, which occurs around E13-E16 in mice and E15-E18 is rats, or first trimester in humans (Peters, 1970), but the adverse outcome does not manifest until adulthood.
There is strong temporal concordance between the various key events, from inhibition of ALDH1A2 (RALDH2) that leads to reduced atRA synthesis. In turn, atRA must be present in the fetal ovaries at the time when oocytes are supposed to enter meiosis mid-gestation in mice (or first trimester in human). With a significant reduction in available atRA the oocytes will not enter meiosis, ultimately leading to the downstream key event of loss of oocytes beyond what is normal. The number of oocytes, or the oocyte pool/ovarian reserve, in turn will affect ovary function and fertility at reproductive stages, hence the temporal sequence of events is rational based on the biological process.
Strength, consistency, and specificity of association of adverse effect and initiating event
In mice, there is strong evidence to support the view that atRA is an inducer of meiosis in germ cells, with consistent results from in vitro (PGCLCs), ex vivo (ovary cultures) and in vivo studies as listed under KE 2477. There is strong evidence showing the importance of RA for female fertility, but this relates to many aspects of reproductive development and function from fetal life to adulthood, including maintaining pregnancy (Clagett-Dame & Knutson, 2011). Thus, it can be difficult to distill exactly how atRA-controlled meiotic entry of oocytes directly link to reduced fertility. Nevertheless, a direct relationship is strongly supported by the fact that Stra8-depleted mice are infertile with small ovaries lacking oocytes (Baltus et al, 2006) and that Stra8 induction in germ cells is controlled by atRA in mice, rats and humans (Bowles et al, 2006; Childs et al, 2011; Koubova et al, 2006; Livera et al, 2000). Furthermore, vitamin A-deficient (VAD) mice display delayed or failed meiotic entry of fetal oocytes depending on level of Vitamin A deficiency (Li & Clagett-Dame, 2009).
Uncertainties, inconsistencies and data gaps
In mice, there is strong evidence to support the view that atRA is important for initiating meiosis in germ cells (Bowles et al, 2016; Spiller et al, 2017; Teletin et al, 2017). Some studies suggest that atAR is not critical but important for meiotic entry under normal physiological conditions by evidencing meiosis in Aldh1a1, Aldh1a2 and Aldh1a3 ablated mice, individually and in tandem (Bellutti et al, 2019; Chassot et al, 2020; Kumar et al, 2011); however, additional studies have shown redundant roles between all three Aldha isoforms which can compensate for deletion of one or two (Bowles et al, 2016). More specifically, both double (Aldh1a2/3) and triple (Aldh1a1/2/3) knockout mouse models display reduced Stra8 expression in oocytes, yet oocytes eventually go through meiosis, which could suggest a redundant role for atRA for meiosis in the ovaries (Chassot et al, 2020; Kumar et al, 2011). A similar phenotype with reduced Stra8 expression but eventual meiotic initiation is seen for deletion of atRA receptors RAR-α, -β, -γ) in mice (Vernet et al, 2020). But, although RAR knockouts were also capable of producing offspring, it remains unclear if any of the above-mentioned mouse models display impaired fertility or whether the size of their oocyte pools are affected.
Quantitative Consideration
This AOP is still largely qualitative, as the quantitative understanding between chemical potency and perturbation of KEs are insufficient. This relates to the dose-response relationship between concentrations of atRA in the ovary relative to meiotic initiation of oocytes. It also relates to the relationship between number of lost oocytes during development relative to the oocyte pool/ovarian reserve, as there naturally is a large loss of oocytes during development.
References
Clagett-Dame M, Knutson D (2011) Vitamin A in Reproduction and Development. Nutrients 3: 385-428
Griswold MD, Hogarth CA, Bowles J, Koopman P (2012) Initiating meiosis: the case for retinoic acid. Biol Reprod 86: 35
Appendix 1
List of MIEs in this AOP
Event: 1880: Inhibition of ALDH1A (RALDH)
Short Name: ALDH1A (RALDH), inhibition
AOPs Including This Key Event
| AOP ID and Name | Event Type |
|---|---|
| Aop:398 - Inhibition of ALDH1A (RALDH) leading to impaired fertility via disrupted meiotic initiation of fetal oogonia of the ovary | MolecularInitiatingEvent |
| Aop:436 - Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries | MolecularInitiatingEvent |
Stressors
| Name |
|---|
| Benomyl |
| WIN18,466 |
| (~13~C,~15~N_2_)Cyanamide |
| Daidzein |
| Molinate |
| Pebulate |
| Vernolate |
| Butylate |
| Tri-allate |
| Cycloate |
Biological Context
| Level of Biological Organization |
|---|
| Molecular |
Cell term
| Cell term |
|---|
| eukaryotic cell |
Domain of Applicability
Taxonomic Applicability| Term | Scientific Term | Evidence | Links |
|---|---|---|---|
| human | Homo sapiens | Moderate | NCBI |
| mouse | Mus musculus | High | NCBI |
| rat | Rattus norvegicus | Moderate | NCBI |
| Life Stage | Evidence |
|---|---|
| All life stages | High |
| Sex | Evidence |
|---|---|
| Male | High |
| Female | High |
The retinoid signaling system is highly conserved across distant animal species (Bushue & Wan, 2010; Rhinn & Dollé, 2012).
Key Event Description
The oxidation of retinal to all-trans retinoic acid (atRA) is an irreversible reaction carried out by retinaldehyde dehydrogenases ALDH1A1, ALDH1A2, ALDH1A3 (RALDH1, RALDH2, RALDH3). ALDH1A2 is responsible for the second step of the metabolism of vitamin A into atRA (Chatzi et al, 2013; Shannon et al, 2017).The role of that reaction is to maintain atRA concentrations, with ALDH1A2 being most active during early development (Koppaka et al, 2012; Shannon et al, 2017). Raldh2-deficient mice exhibit severe developmental defects due to loss of atRA, but the phenotype is rescued by administration of exogenous RA (Niederreither et al, 1999). Thus, ALDH1A2 activity is essential for atRA-dependent developmental processes.
How it is Measured or Detected
There are no OECD validated assays for measuring ALDH1A2 inhibition.
ALDH1A2 mRNA and protein levels can be measured using various probes, antibodies as well as ELISA kits that are commercially available.
Enzyme activity can be assessed in assays including measurement of atRA formation (Arnold et al, 2015) or NADH formation (Harper et al, 2018; Schindler et al, 1998) and several ALDH activity assay kits using different approaches are commercially available; e.g. AldeflourTM kit (Flahaut et al, 2016).
References
Bushue N, Wan YJY (2010) Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 62: 1285-1298
Rhinn M, Dollé P (2012) Retinoic acid signalling during development. Development 139: 843-858
List of Key Events in the AOP
Event: 1881: Decreased, all-trans retinoic acid (atRA) concentration
Short Name: Decreased, atRA concentration
AOPs Including This Key Event
Stressors
| Name |
|---|
| WIN18,466 |
| Ethanol |
| Diethylaminobenzaldehyde |
Biological Context
| Level of Biological Organization |
|---|
| Tissue |
Domain of Applicability
Taxonomic Applicability| Term | Scientific Term | Evidence | Links |
|---|---|---|---|
| mouse | Mus musculus | High | NCBI |
| rat | Rattus norvegicus | High | NCBI |
| human | Homo sapiens | High | NCBI |
| Vertebrates | Vertebrates | Moderate | NCBI |
| Life Stage | Evidence |
|---|---|
| All life stages | Moderate |
| Sex | Evidence |
|---|---|
| Male | High |
| Female | High |
The retinoid signaling system is highly conserved across animal species (Bushue & Wan, 2010b; Rhinn & Dollé, 2012). atRA acts as a ligand for the nuclear retinoic acid (RAR) receptors, which upon activation regulate gene transcription in target cells. The type and number of RARs differ between evolutionary distant animals, but functionally they are all involved in the regulation of development.
Key Event Description
All-trans retinoic acid (atRA) is the active form of vitamin A/all-trans retinol and is involved in regulating a large number of developmental processes (Bushue & Wan, 2010a; Ghyselinck & Duester, 2019). Although 9-cis RA and 13-cis RA are other metabolic derivatives of vitamin A, atRA is generally considered the primary active metabolite during development, mainly acting as a short-range paracrine signaling molecule (Cunningham & Duester, 2015). atRA exerts dose-dependent effects on morphogenesis, so disruption to atRA concentrations during development can lead to malformations in numerous tissues and organs. During development the spatiotemporal regulation of atRA concentrations in target tissues is tightly controlled by a balance of synthesis and degradation enzymes (Kedishvili, 2013).
Cellular atRA synthesis starts by oxidation of vitamin A to retinaldehyde (RAL) by retinol dehydrogenase-10 (RDH10). RAL is then irreversibly converted to atRA by RAL dehydrogenases (ALDH1A1, ALD1A2, or ALDH1A3). To maintain appropriate retinoid levels in tissues, RAL can be converted back to retinol by enzymatic reactions; further retinoid levels can be controlled by enzymatic degradation of atRA by the cytochrome P450 enzymes CYP26A1, CYP26B1, or CYP26C1, which are differentially expressed throughout the mammalian body (Isoherranen & Zhong, 2019; Shimozono et al, 2013). Inhibition/disruption of any of the enzymes of the atRA synthesis pathway, or increased expression of the atRA degradation enzymes can lead to decreased concentrations of atRA in target cells (Kedishvili, 2013).
The atRA functions as a ligand for the nuclear retinoic acid receptors (RARs), which form heterodimers with the retinoid X receptors (RXRs); the atRA:RAR:RXR complex then binds to retinoic acid response elements (RAREs) upstream of target genes, leading to activation or repression of gene expression in target cells (Chambon, 1996; le Maire et al, 2019). The type and number of RAR/RXRs differ between evolutionary distant animals, but functionally they are all involved in the regulation of development (Gutierrez-Mazariegos et al, 2014).
How it is Measured or Detected
Direct measurements of atRA in serum (humans, animals) can be performed by various chromatographic methods (Gundersen, 2006), including high performance liquid chromatography (HPLC) or liquid chromatography-tandem mass spectrometry (LC-MS) (Morgenstern et al, 2021).
Indirect measurements in cells and animal models can be performed with reporter assays utilizing RAR-RXR-RARE or RXR-RXR-RARE promoter elements, which are activated by atRA, driving expression of reporter proteins. These reporter assays can detect the presence of atRA in tissues in a semi-quantitative manner. Examples include reporter mouse lines (Carlsen et al, 2021; Rossant et al, 1991; Solomin et al, 1998), reporter cell lines (Wagner et al, 1992) and transient transfection of constructs for in vitro cell-based assays (Chassot et al, 2020).
References
Bushue N, Wan YJ (2010a) Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 62: 1285-1298
Bushue N, Wan YJY (2010b) Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 62: 1285-1298
Chambon P (1996) A decade of molecular biology of retinoic acid receptors. FASEB J 10: 940-954
Ghyselinck NB, Duester G (2019) Retinoic acid signaling pathways. Development 146
Rhinn M, Dollé P (2012) Retinoic acid signalling during development. Development 139: 843-858
Event: 1882: Disrupted meiotic initiation of fetal oogonia of the ovary
Short Name: Oocyte meiosis, disrupted
AOPs Including This Key Event
| AOP ID and Name | Event Type |
|---|---|
| Aop:398 - Inhibition of ALDH1A (RALDH) leading to impaired fertility via disrupted meiotic initiation of fetal oogonia of the ovary | KeyEvent |
Stressors
| Name |
|---|
| Acetaminophen |
| Indomethacin |
| Bis(2-ethylhexyl) phthalate |
| Bisphenol A |
Biological Context
| Level of Biological Organization |
|---|
| Cellular |
Organ term
| Organ term |
|---|
| ovary sex cord |
Domain of Applicability
Taxonomic Applicability| Term | Scientific Term | Evidence | Links |
|---|---|---|---|
| mouse | Mus musculus | High | NCBI |
| human | Homo sapiens | High | NCBI |
| rat | Rattus norvegicus | High | NCBI |
| Life Stage | Evidence |
|---|---|
| Foetal | High |
| Development | High |
| Sex | Evidence |
|---|---|
| Female | High |
Fetal oocytes need to enter meiosis prophase I to maintain the oocyte population and establish the oocyte pool. This process in conserver between mice, rats and humans.
Key Event Description
Oocyte meiosis
Oogonia, the female germ cells, are the precursors for the female oocytes. Primary oocytes are formed in the ovaries during fetal development when oogonia enter into prophase I of meiosis; meiotic entry initiates at around embryonic (E) day 13.5 in mice, E15.5 in rats, and gestational week 10-12 in humans. The entry into meiosis is driven by expression of the key genes Stra8, Meiosin and Rec8 and is followed by expression of meiotic proteins including SYCP3 and γH2AX (Baltus et al, 2006; Bowles et al, 2006; Ishiguro et al, 2020; Kojima et al, 2019; Koubova et al, 2014; Spiller et al, 2017). The crucial role for Stra8 in meiotic entry is conserved from mice to humans (Childs et al, 2011).
Disrupted meiotic entry as Key Event
The initiation of meiosis during fetal life is critical for maintenance of the oocytes throughout development and, eventually, for establishing the oocyte pool, or ‘oocyte reserve’ at birth. Without timely fetal entry into meiosis, the oogonia are depleted, as evidenced in Stra8-null mice (Baltus et al, 2006). The Stra8-null female mice are infertile and display abnormally small ovaries that are devoid of oocytes. For Stra8 to be expressed and, therefore, for meiosis to initiate, the oogonia require direct stimulation by atRA as evidenced in mice (Bowles et al, 2016; Bowles et al, 2006; Feng et al, 2021; Koubova et al, 2006; Spiller et al, 2017; Teletin et al, 2017), and humans (Childs et al, 2011; Le Bouffant et al, 2010).
How it is Measured or Detected
There are no OECD-validated assays for measuring meiotic inhibition.
The expression of meiotic factors, such as STRA8, SYCP3, γH2AX, can be assessed at mRNA and/or protein levels and levels measured using primers/probes and antibodies that are commercially available.
Indirect measurements in animal models can be performed using the Stra8 promoter element driving expression of reporter protein GFP (Feng et al, 2021). This reporter assay can detect the presence (GFP) or absence (GFP negative) of Stra8 promoter activation in a semi-quantitative manner.
References
Event: 1883: Reduced size of the ovarian follicle pool
Short Name: Ovarian follicle pool, reduced
AOPs Including This Key Event
| AOP ID and Name | Event Type |
|---|---|
| Aop:398 - Inhibition of ALDH1A (RALDH) leading to impaired fertility via disrupted meiotic initiation of fetal oogonia of the ovary | KeyEvent |
Stressors
| Name |
|---|
| Diethylstilbestrol |
| Bisphenol A |
| Genistein |
| Bis(2,4,6-trimethylphenyl)-lambda~2~-germane--selenium (1/1) |
Biological Context
| Level of Biological Organization |
|---|
| Organ |
Organ term
| Organ term |
|---|
| ovary sex cord |
Domain of Applicability
Taxonomic Applicability| Term | Scientific Term | Evidence | Links |
|---|---|---|---|
| mouse | Mus musculus | High | NCBI |
| human | Homo sapiens | High | NCBI |
| rat | Rattus norvegicus | High | NCBI |
| Life Stage | Evidence |
|---|---|
| Fetal | High |
| Sex | Evidence |
|---|---|
| Female | High |
Follicle assembly occur in females during fetal life (humans) or around and after birth (rodents). Many of the mechanisms involved are preserved between mice, rats and humans.
Key Event Description
Formation of the follicle pool (follicle assembly)
During fetal life, primordial germ cells migrate to the genital ridges where they arrange into germ cell nests and proceed through to meiosis prophase I (Pepling & Spradling, 2001). Assembly into individual follicles occurs via mechanisms that are not well known, but involves germ cell nest break down and a reduction in oocyte numbers via programmed cell death. Somatic pre-granulosa cells infiltrate between the oocytes, arrange around them in a single layer, and establish what is called the primordial follicles (Escobar et al, 2008; Gawriluk et al, 2011; Pepling & Spradling, 2001). The primordial follicles constitute the follicle pool - a limited stock of oocytes that are available for maturation and potential fertilization determining the length of a female’s reproductive life span (Grive & Freiman, 2015).
The timing of follicle assembly differs between mammalian species, but the processes involved seem to be relatively well conserved (Grive & Freiman, 2015). In humans, follicle assembly occurs during mid-gestation whereas in mice and rats it is initiated around the time of birth and continues until approximately six days post partum.
Reduced follicle pool as Key Event
An intact follicle pool is critical for female fertility. Any disruption to the formation of the final pool can have adverse consequences for reproductive capacity, leading to sub- or infertility. Loss of oocytes/follicles can occur during any of the abovementioned stages during the process of follicle assembly – oocyte nest breakdown, programmed cell death or somatic pre-granulosa cell intrusion. Follicle assembly and establishment of the functional follicle pool is also dependent on the stages occurring before this process, e.g. migration of primordial germ cells to the genital ridges, sex determination and meiosis.
How it is Measured or Detected
In animal studies, counting of follicles of different sizes is included in OECD guidelines: TG 416 (Two-Generation Reproductive Toxicity Study) and TG 443 (Extended One-Generation Reproductive Toxicity Study). It is a time-consuming and labor-intensive method and it is not recommended to compare values between studies (Tilly, 2003).
In humans, there is no direct way to count the follicle pool in vivo. Instead, surrogate markers are used. The most established biomarker for estimation of the follicle pool is anti-Müllerian hormone (AMH). It is readily measured in a blood sample and the levels are rather stable throughout the menstrual cycle (Broer et al, 2014).
The size of the pool can also be measured indirectly by mRNA and protein expression of meiotic markers, or by assessing overall ovary histology by histological assessments (Zhang et al, 2012).
References
Tilly JL (2003) Ovarian follicle counts--not as simple as 1, 2, 3. Reprod Biol Endocrinol 1: 11
Event: 405: irregularities, ovarian cycle
Short Name: irregularities, ovarian cycle
Key Event Component
| Process | Object | Action |
|---|---|---|
| ovulation cycle | disrupted |
AOPs Including This Key Event
Biological Context
| Level of Biological Organization |
|---|
| Individual |
Domain of Applicability
Taxonomic ApplicabilityThe estrous cycle comprises the recurring physiologic changes that are induced by reproductive hormones in most mammalian females. Many of the mechanisms involved in the regulation of the reproductive axis are similar across species (particularly those mediated through the estrogen receptor), assessments of rodent estrous cyclicity can offer insight into potential adverse effects in humans (Goldman, Murr, & Cooper, 2007). While evaluations of vaginal cytology in the laboratory rodent can provide a valuable reflection of the integrity of the hypothalamic-pituitary-ovarian axis, other indices are more useful in humans to determine the functional status of the reproductive system (e.g. menses, basal body temperature, alterations in vaginal pH, cervical mucous viscosity, and blood hormone levels). Nevertheless, since many of the mechanisms involved in the regulation of the reproductive axis are similar across species (particularly those mediated through the estrogen receptor), assessments of rodent estrous cyclicity can offer insight into potential adverse effects in humans (Rasier, Toppari, Parent, & Bourguignon, 2006).
Key Event Description
Biological state
The female ovarian cycle is the result of a balanced cooperation between several organs and is determined by a complex interaction of hormones. Ovarian cycle irregularities include disturbances in the ovarian cycle (e.g. longer cycle, persistent estrus) and/or ovulation problems (deferred ovulation or anovulation). The estrous cycle (also oestrous cycle) comprises the recurring physiologic changes that are induced by reproductive hormones in females. Estrous cycles start after sexual maturity in females and are interrupted by anestrous phases or pregnancies. During this cycle numerous well defined and sequential alterations in reproductive tract histology, physiology and cytology occur, initiated and regulated by the hypothalamic-pituitary-ovarian (HPO) axis. The central feature of the mammalian estrous cycle is the periodic maturation of eggs that will be released at ovulation and luteinisation of the follicles after ovulation to form corpora lutea. Adapted from www.oecd.org/chemicalsafety/testing/43754807.pdf Biological compartments
The cyclic changes that occur in the female reproductive tract are initiated and regulated by the hypothalamic-pituitary-ovarian (HPO) axis. Although folliculogenesis occurs independently of hormonal stimulation up until the formation of early tertiary follicles, the gonadotrophins luteinising hormone (LH) and follicle stimulating hormone (FSH) are essential for the completion of follicular maturation and development of mature preovulatory (Graafian) follicles. The oestrous cycle consists of four stages: prooestrus, oestrus, metoestrus (or dioestrus 1) and dioestrus (or dioestrus 2) orchestrated by hormones. Levels of LH and FSH begin to increase just after dioestrus. Both hormones are secreted by the same secretory cells (gonadotrophs) in the pars distalis of the anterior pituitary (adenohypophysis). FSH stimulates the development of the zona granulosa and triggers expression of LH receptors by granulosa cells. LH initiates the synthesis and secretion of androstenedione and, to a lesser extent, testosterone by the theca interna; these androgens are utilised by granulosa cells as substrates in the synthesis of estrogen. Pituitary release of gonadotrophins thus drives follicular maturation and secretion of estrogen during prooestrus. Gonadotrophin secretion by the anterior pituitary is regulated by luteinising hormone-releasing hormone (LHRH), produced by the hypothalamus. LHRH is transported along the axons of hypothalamic neurones to the median eminence where it is secreted into the hypothalamic-hypophyseal portal system and transported to the anterior pituitary. The hypothalamus secretes LHRH in rhythmic pulses; this pulsatility is essential for the normal activation of gonadotrophs and subsequent release of LH and FSH. Adapted from www.oecd.org/chemicalsafety/testing/43754807.pdf
Follicles that produce estrogens have sequestered pituitary FSH which in turn stimulates the aromatase reaction. Such follicles can undergo normal development and ovulation and contain eggs that readily resume meiosis when released. In the absence of an active local aromatase (i.e., no follicle-stimulating hormone), the follicles and oocytes become atretic and regress without ovulating. If aromatase is present, the estrogen and follicle stimulating hormone can further develop the follicular cells for normal luteal function after ovulation takes place (Ryan, 1982).
General role in biology
A sequential progression of interrelated physiological and behavioural cycles underlines the female's successful production of young. In many but not all species the first and most basic of these is estrous cycle, which is itself a combination of cycles.
How it is Measured or Detected
Methods that have been previously reviewed and approved by a recognized authority should be included in the Overview section above. All other methods, including those well established in the published literature, should be described here. Consider the following criteria when describing each method: 1. Is the assay fit for purpose? 2. Is the assay directly or indirectly (i.e. a surrogate) related to a key event relevant to the final adverse effect in question? 3. Is the assay repeatable? 4. Is the assay reproducible?
The pattern of events in the estrous cycle may provide a useful indicator of the normality of reproductive neuroendocrine and ovarian function in the nonpregnant female. It also provides a means to interpret hormonal, histologic, and morphologic measurements relative to stage of the cycle, and can be useful to monitor the status of mated females.
Regular cyclicity is one of the key parameters in assessment of female reproductive function in rodents.
Parameters assessed for cyclicity:
- Number of cycling females
- Number of females with regular cycles
- Number of cycles
- Estrous cycle length
- Percentage of time spent in the various estrous cycle stages
Estrous cyclicity provides a method for evaluating the endocrine disrupting activity of each test chemical under physiologic conditions where endogenous concentrations of estrogen vary. Abnormal cycles were defined as one or more estrous cycles in the 21-day period with prolonged estrus (≥3 days) and/or prolonged metestrus or diestrus (≥4 days) within a given cycle (Goldman, Murr, & Cooper, 2007).
Estrous cycle normality can be monitored in the rat and mouse by observing the changes in the vaginal smear cytology. Visual observation of the vagina is the quickest method, requires no special equipment, and is best used when only proestrus or estrus stages need to be identified. For details see: (Westwood, 2008), (Byers, Wiles, Dunn, & Taft, 2012) and OECD guidelines (www.oecd.org).
The observation that animals do not ovulate while exhibiting estrous cycles indicates that estrous cyclicity alone may not be a sufficient surrogate of healthy function of ovaries; the measurements of serum hormones and particularly FSH can contribute to more sensitivity indicators of healthy function of ovaries (Davis, Maronpot, & Heindel, 1994).
Monitoring of oestrus cyclicity is included in OECD test guidelines (Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents, 2008) [1], (Test No. 416: Two-Generation Reproduction Toxicity, 2001)[2] and (Test No. 443: Extended One-Generation Reproductive Toxicity Study, 2012) [3]and in USA EPA OCSPP 890.1450.
In vitro testing
The follicle culture models were developed for the in-vitro production of mature oocytes and used to study the process of folliculogenesis and oogenesis in vitro (Cortvrindt & Smitz, 2002). These in vitro cultures demonstrate near-identical effects to those found in vivo, therefore might be able to acquire a place in fertility testing, replacing some in-vivo studies for ovarian function and female gamete quality testing (Stefansdottir, Fowler, Powles-Glover, Anderson, & Spears, 2014).
Regulatory Significance of the AO
Chemicals may be found to interfere with reproductive function in the female rat. This interference is commonly expressed as a change in normal morphology of the reproductive tract or a disturbance in the duration of particular phases of the estrous cycle. This key event lies within the scope of testing for endocrine disrupting activity of chemicals and therefore for testing of female reproductive and developmental toxicity. Monitoring of oestrus cyclicity is included in OECD test guidelines (Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents, 2008), (Test No. 416: Two-Generation Reproduction Toxicity, 2001) and (Test No. 443: Extended One-Generation Reproductive Toxicity Study, 2012) and in USA EPA OCSPP 890.1450. While an evaluation of the estrous cycle in laboratory rodents can be a useful measure of the integrity of the hypothalamic-pituitary-ovarian reproductive axis, it can also serve as a way of insuring that animals exhibiting abnormal cycling patterns are excluded from a study prior to exposure to a test compound. When incorporated as an adjunct to other endpoint measures, a determination of a female's cycling status can contribute important information about the nature of a toxicant insult to the reproductive system. In doing so, it can help to integrate the data into a more comprehensive mechanistic portrait of the effect, and in terms of risk assessment, may provide some indication of a toxicant's impact on human reproductive physiology. Significant evidence that the estrous cycle (or menstrual cycle in primates) has been disrupted should be considered an adverse effect (OECD, 2008). Included should be evidence of abnormal cycle length or pattern, ovulation failure, or abnormal menstruation.
References
Byers, S. L., Wiles, M. V, Dunn, S. L., & Taft, R. A. (2012). Mouse estrous cycle identification tool and images. PloS One, 7(4), e35538. doi:10.1371/journal.pone.0035538
Cortvrindt, R. G., & Smitz, J. E. J. (2002). Follicle culture in reproductive toxicology: a tool for in-vitro testing of ovarian function? Human Reproduction Update, 8(3), 243–54.
Davis, B. J., Maronpot, R. R., & Heindel, J. J. (1994). Di-(2-ethylhexyl) phthalate suppresses estradiol and ovulation in cycling rats. Toxicology and Applied Pharmacology, 128(2), 216–23. doi:10.1006/taap.1994.1200
Goldman, J. M., Murr, A. S., & Cooper, R. L. (2007). The rodent estrous cycle: characterization of vaginal cytology and its utility in toxicological studies. Birth Defects Research. Part B, Developmental and Reproductive Toxicology, 80(2), 84–97. doi:10.1002/bdrb.20106
OECD. (2008). No 43: Guidance document on mammalian reproductive toxicity testing and assessment.
Rasier, G., Toppari, J., Parent, A.-S., & Bourguignon, J.-P. (2006). Female sexual maturation and reproduction after prepubertal exposure to estrogens and endocrine disrupting chemicals: a review of rodent and human data. Molecular and Cellular Endocrinology, 254-255, 187–201. doi:10.1016/j.mce.2006.04.002
Ryan, K. J. (1982). Biochemistry of aromatase: significance to female reproductive physiology. Cancer Research, 42(8 Suppl), 3342s–3344s.
Stefansdottir, A., Fowler, P. A., Powles-Glover, N., Anderson, R. A., & Spears, N. (2014). Use of ovary culture techniques in reproductive toxicology. Reproductive Toxicology (Elmsford, N.Y.), 49C, 117–135. doi:10.1016/j.reprotox.2014.08.001
Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents. (2008). OECD Publishing. doi:10.1787/9789264070684-en
Test No. 416: Two-Generation Reproduction Toxicity. (2001). OECD Publishing. doi:10.1787/9789264070868-en
Test No. 443: Extended One-Generation Reproductive Toxicity Study. (2012). OECD Publishing. doi:10.1787/9789264185371-en
Westwood, F. R. (2008). The female rat reproductive cycle: a practical histological guide to staging. Toxicologic Pathology, 36(3), 375–84. doi:10.1177/0192623308315665
List of Adverse Outcomes in this AOP
Event: 406: impaired, Fertility
Short Name: impaired, Fertility
Key Event Component
| Process | Object | Action |
|---|---|---|
| fertility | decreased |
AOPs Including This Key Event
Biological Context
| Level of Biological Organization |
|---|
| Individual |
Domain of Applicability
Taxonomic Applicability| Term | Scientific Term | Evidence | Links |
|---|---|---|---|
| rat | Rattus norvegicus | High | NCBI |
| mouse | Mus musculus | High | NCBI |
| human | Homo sapiens | High | NCBI |
| Life Stage | Evidence |
|---|---|
| Adult, reproductively mature | High |
| Juvenile | High |
| Adults | High |
Plausible domain of applicability
Taxonomic applicability: The impaired fertility may also have relevance for fish, mammals, amphibians, reptiles, birds and and invertebrates with sexual reproduction.
Life stage applicability: The impaired fertility can be measured at juveniles and adults.
Sex applicability: The impaired fertility can be measured in both male and female species.
Key Event Description
Biological state
capability to produce offspring
Biological compartments
System
General role in biology
Fertility is the capacity to conceive or induce conception. Impairment of fertility represents disorders of male or female reproductive functions or capacity.
How it is Measured or Detected
As a measure, fertility rate, is the number of offspring born per mating pair, individual or population.
Regulatory Significance of the AO
Under REACH, information on reproductive toxicity is required for chemicals with an annual production/importation volume of 10 metric tonnes or more. Standard information requirements include a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study (OECD 414) on a first species at Annex IX (100-1000 t.p.a), and from March 2015 the OECD 443(Extended One-Generation Reproductive Toxicity Study) is reproductive toxicity requirement instead of the two generation reproductive toxicity study (OECD TG 416). If not conducted already at Annex IX, a prenatal developmental toxicity study on a second species at Annex X (≥ 1000 t.p.a.).
Under the Biocidal Products Regulation (BPR), information is also required on reproductive toxicity for active substances as part of core data set and additional data set (EU 2012, ECHA 2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative approach to the multi-generation study.) According to the Classification, Labelling and Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) “reproductive toxicity” includes adverse effects on sexual function and fertility in adult males and females, as well as developmental toxicity in the offspring; b) “effects on fertility” includes adverse effects on sexual function and fertility; and c) “developmental toxicity” includes adverse effects on development of the offspring.
References
OECD (2001), Test No. 416: Two-Generation Reproduction Toxicity, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, https://doi.org/10.1787/9789264070868-en.
OECD (2018), Test No. 443: Extended One-Generation Reproductive Toxicity Study, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, https://doi.org/10.1787/9789264185371-en.
OECD (2018), Test No. 414: Prenatal Developmental Toxicity Study, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, https://doi.org/10.1787/9789264070820-en.
OECD (2018), "Reproduction/Developmental Toxicity Screening Test (OECD TG 421) and Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test (OECD TG 422)", in Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption, OECD Publishing, Paris, https://doi.org/10.1787/9789264304741-25-en.
Appendix 2
List of Key Event Relationships in the AOP
List of Adjacent Key Event Relationships
Relationship: 2401: ALDH1A (RALDH), inhibition leads to Decreased, atRA concentration
AOPs Referencing Relationship
| AOP Name | Adjacency | Weight of Evidence | Quantitative Understanding |
|---|---|---|---|
| Inhibition of ALDH1A (RALDH) leading to impaired fertility via disrupted meiotic initiation of fetal oogonia of the ovary | adjacent | High | Moderate |
| Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries | adjacent | High | Moderate |
Evidence Supporting Applicability of this Relationship
| Life Stage | Evidence |
|---|---|
| All life stages |
| Sex | Evidence |
|---|---|
| Male | High |
| Female | High |
Key Event Relationship Description
All-trans retinoic acid (atRA) is the active metabolite of vitamin A in developing mammals and its physiological levels is tightly regulated by enzymatic pathways. This KER is particularly relevant for mammalian embryogenesis/fetal development stages.
atRA is synthesized from dietary vitamin A (retinol) by a two-step oxidation pathway (Chatzi et al, 2013; Kedishvili, 2016): 1) retinol dehydrogenase (RDH10) metabolizes retinol to retinaldehyde (reversible step), 2) retinaldehyde dehydrogenase ALDH1A (ALDH1A1, ALDH1A2, ALDH1A3) metabolizes retinaldehyde to RA (irreversible step). All three isoenzymes can carry out the second (irreversible step) to produce atRA, but ALDH1A2 is the most active form during development (Kedishvili, 2016). Thus, inhibition of ALDH1A2 during development will decrease atRA concentrations.
Evidence Supporting this KER
Evidence showing that retinaldehyde dehydrogenases is responsible for the irreversible oxidation of retinal to retinoic acid was provided by several studies in the 1960s, using calf and rat livers (Dmitrovskii, 1961; Dunagin Jr et al, 1964; Elder & Topper, 1962; Futterman, 1962; Lakshmanan et al, 1964; Mahadevan et al, 1962), as reviewed by (Kedishvili, 2016). The identification of the three isoenzymes ALDH1A1 (RALDH1), ALDH1A2 (RALDH2), ALDH1A3 (RALDH3) followed during 1980-1990 (Kedishvili, 2016). It is now considered canonical knowledge that the three retinaldehyde dehydrogenases are responsible for the in vivo biosynthesis of retinoic acid from retinal (Marchitti et al, 2008; Napoli, 2012).
Biological PlausibilityEmbryogenesis/fetal development in mammals
Of the three isoenzymes, ALDH1A2 is the most active form during early development in mammals. This is evidenced in mice ablated for Aldh1a2 (Raldh2-/-), which are incapable of producing atRA and present with severe developmental defects (Niederreither et al, 1999). Conversely, mice lacking Aldh1a1 or Aldh1a3 survive fetal development, with phenotypes presenting postnatally (Dupé et al, 2003; Fan et al, 2003; Molotkov & Duester, 2003). Thus, the biological plausibility that inhibition of ALDH1A2 will lead to decreased atRA in cells and tissues during development is strong.
Empirical EvidenceThe empirical evidence for linkage is strong and widely accepted. The enzymatic activity of ALDH1A2 and capacity to oxidize retinal has been proven in vitro (see KE 1880). In vivo, the strongest evidence comes from the Aldh1a2-deficient mice that fail to synthesize retinoic acid during embryogenesis (Niederreither et al, 1999). Additionally, ovary culture with the potent ALDH1A2 inhibitor WIN18,446 results in failure to upregulate the atRA-regulated gene Stra8 in oocytes, resulting in germ cell loss (Rosario et al, 2020). Additional evidence for this relationship using WIN18,466 also comes from in vivo studies looking at spermatogenesis; inhibition of ALDH1A2 via WIN18,466 results in loss of atRA expression and halted spermatogenesis in diverse species such as mice, rabbits and zebrafish (Amory et al, 2011; Paik et al, 2014; Pradhan & Olsson, 2015).
Quantitative Understanding of the Linkage
The distribution of retinoic acid in cells and tissues are highly variable, as has been shown across species including chicken (Maden et al, 1998), frogs (Chen et al, 1994), mice (Kane et al, 2005; Obrochta et al, 2014) and rats (Bhat, 1997), as well as serum/plasma from humans (Kane et al, 2008; Miyagi et al, 2001; Napoli et al, 1985).
The exact relationship between ALDH1A2 inhibition and resulting atRA concentrations in mammalian ovaries is unclear. The ALDH1A2 inhibitor WIN18,446 inhibits enzyme activity in vitro with an IC(50) of 0.3 μM (Amory et al, 2011), and a dose of only 0.01 µM is sufficient to significantly reduce expression of Stra8 in cultured mouse fetal ovaries and with actual loss of oocytes from 2 µM (Rosario et al, 2020).
Time-scaleSince atRA must be enzymatically synthesized by ALDH1A enzymes (in this case ALDH1A2), the temporal and linear relationship between the two KEs are essential.
Known Feedforward/Feedback loops influencing this KERRetinoic acid status is regulated by complex feedback loops. For instance, atRA induces expression of retinoid enzymes to promote synthesis of retinyl esters, but simultaneously atRA induces expression of its own catabolizing CYP26 enzymes (Kedishvili, 2013; Kedishvili, 2016; Teletin et al, 2017).
References
Kedishvili NY (2016) Retinoic Acid Synthesis and Degradation. Subcell Biochem 81: 127-161
Relationship: 2477: Decreased, atRA concentration leads to Oocyte meiosis, disrupted
AOPs Referencing Relationship
| AOP Name | Adjacency | Weight of Evidence | Quantitative Understanding |
|---|---|---|---|
| Inhibition of ALDH1A (RALDH) leading to impaired fertility via disrupted meiotic initiation of fetal oogonia of the ovary | adjacent | Moderate | Low |
Evidence Supporting Applicability of this Relationship
| Life Stage | Evidence |
|---|---|
| Foetal | High |
| Sex | Evidence |
|---|---|
| Female | High |
Key Event Relationship Description
All-trans retinoic acid (atRA) is the active metabolite of vitamin A and is involved in regulating a large number of developmental processes (Bushue & Wan, 2010; Ghyselinck & Duester, 2019). atRA is produced in spatial and temporal gradients, and these patterns are maintained by regulated expression of the synthesis and degradation enzymes of the atRA pathway (Kedishvili, 2013).The presence of atRA in the fetal ovaries induces germ cells to enter meiosis (Spiller et al, 2017). The initiation of meiosis at this time during fetal life is critical for maintenance of the germ line throughout development and establishment of the oocyte pool at birth. If atRA is not present at the correct time and at sufficient concentration, meiotic initiation is either delayed or prevented from occurring, ultimately disrupting germ cell development.
All-trans retinoic acid (atRA) is the active metabolite of vitamin A and is involved in regulating a large number of developmental processes (Bushue & Wan, 2010; Ghyselinck & Duester, 2019). atRA is produced in spatial and temporal gradients, and these patterns are maintained by regulated expression of the synthesis and degradation enzymes of the atRA pathway (Kedishvili, 2013).
The presence of atRA in the fetal ovaries induces germ cells to enter meiosis (Spiller et al, 2017). The initiation of meiosis at this time during fetal life is critical for maintenance of the germ line throughout development and establishment of the oocyte pool at birth. If atRA is not present at the correct time and at sufficient concentration, meiotic initiation is either delayed or prevented from occurring, ultimately disrupting germ cell development.
Evidence Supporting this KER
The majority of evidence for this KER comes from rodent studies. In pregnant rats, depletion of vitamin A, the precursor of atRA, leads to an inability of ovarian germ cells to initiate meiosis (Li & Clagett-Dame, 2009). Further studies in mice have produced strong evidence that atRA acts as a meiosis-inducing factor in oogonia of the ovaries, although there are some conflicting data depending on which techniques are used (Griswold et al, 2012; Spiller & Bowles, 2022). Evidence for the same mechanisms in human fetal ovaries is less substantiated and there may be species differences, particularly the manner in which atRA is made available (reviewed by (Jørgensen & Rajpert-De Meyts, 2014). In humans, evidence to support the KER comes from studies using explanted ovary culture.
Biological PlausibilityIn mammalian germ cells, the initiation and progression of meiosis is critically dependent on the expression of Stimulated by retinoic acid gene 8 (Stra8). In mice, deleting Stra8 leads to infertility in both males and females due to meiotic failure (Anderson et al, 2008; Baltus et al, 2006; Mark et al, 2008). What regulates the temporal expression of Stra8, and other factors (such as Rec8 and Dazl) in the germ cells is not completely clear, but there is strong evidence to support an important role for atRA (Bowles et al, 2006; Feng et al, 2021; Griswold et al, 2012; Koubova et al, 2014; Soh et al, 2015).
In the fetal mouse ovary, entry into meiosis, preceded by Stra8 expression, occurs in an overlapping anterior-to-posterior wave from E12.5 (Bowles et al, 2006; Menke et al, 2003). Stra8 is also expressed in rat oogonia at comparative developmental stages to the mouse (Liu et al, 2020). atRA can similarly upregulate Stra8 in vitro, but this is restricted to pluripotent cell lines(Feng et al, 2021; Oulad-Abdelghani et al, 1996; Wang et al, 2016). Culture of mouse skin-derived stem cells with atRA stimulates the formation of functioning gametes and improves oogonia-like cells entry into meiosis (Dyce et al, 2018; Miyauchi et al, 2017). Stra8 expression cannot be induced by atRA in non-pluripotent cell lines, nor in somatic cells in vivo (Feng et al, 2021).
Exposure of pre-meiotic tammar (marsupial) ovaries to atRA induces Stra8 expression and oogonial meiotic entry (Hickford et al, 2017). Culturing fetal mouse ovaries in the presence of atRA increases the number of meiotic oocytes (Livera et al, 2000) and the same phenomenon is observed in cultured human fetal ovaries (Jørgensen et al, 2015).
In mouse ovaries lacking the atRA synthesizing enzyme ALDH1A1, the onset of germ cell meiosis is delayed (Bowles et al, 2016). This supports a previous study showing that atRA derived from the ovary (rather than mesonephros) is sufficient to initiate meiosis in mice (Mu et al, 2013). In humans, the local synthesis of atRA by ALDH1A enzymes within the ovary may also be involved in meiotic regulation (Childs et al, 2011; Le Bouffant et al, 2010). In two recent studies looking at mouse ovaries lacking all known atRA synthesizing enzymes (Chassot et al, 2020) or RA receptors (Vernet et al, 2020), expression of Stra8 was delayed, albeit some meiosis was still observed in these mice.
Empirical EvidenceAnimal models
|
Model |
Relevant observations |
Reference |
|
Vitamin A deficient (VAD) rats |
Oocytes fail to enter meiosis in ovaries of VAT rats due to atAR deficiency. Meiotic entry measured by SYCP3 expression was detected in 10% and 30% of germ cells in rats fed severely deficient (1.5ug of atRA per gram of diet) and moderately deficient (12ug of atRA per gram of diet) atRA diets, respectively, whilst controls had 70% of germ cells enter meiosis. The expression of the atRA-responsive gene, Stra8, was reduced by approximately 90% and 50% in the severely and moderately atRA-deficient ovaries, respectively, compared with the atRA-sufficient controls. |
In vitro/ex vivo
|
Study type |
Species |
Compound |
Effect Dose |
Duration |
Results |
Reference |
|
Fetal ovaries in culture |
Mouse |
WIN 18,446 (ALDH1A2 inhibitor) |
2 µM |
3-12 d |
Reduced Stra8 expression and germ cell loss. |
|
|
Fetal ovaries in culture |
Mouse |
BMS-189453 (RAR antagonist) |
1 µM |
3 d |
Reduced STRA8-positve germ cells without overall oocyte loss |
|
|
Embryonic stem cells |
Mouse |
ATRA |
100 nM |
|
Activates meiosis-related gene network |
|
|
Embryonic stem cells |
Mouse |
BMS-493 (RAR antagonist) |
10 µM |
|
Inhibition of expression meiosis-related genes |
|
|
Naked oocytes, matured |
Mouse |
ATRA |
2 µM |
24 h |
Culture in presence of atRA increased meiosis resumption and formation of metaphase II oocytes |
|
|
fetal ovaries in culture |
Human |
ATRA |
1 µM |
1-3 d |
atRA strongly promote initiation of germ cell meiosis |
|
|
fetal ovaries in culture |
Human |
BMS-189453 (RAR antagonist) |
10 µM |
14 d |
Partial inhibition of meiotic entry of germ cells |
|
|
fetal ovaries in culture |
Human |
Citral |
55 µM |
14 d |
Partial inhibition of meiotic entry of germ cells by inhibiting RA synthesizing enzymes |
|
|
Fetal ovaries in culture |
Mouse |
AGN193109 (RAR antagonist) |
5 µM |
48 h or 72 h |
Meiotic program inhibited |
|
|
Fetal ovaries in culture |
Mouse |
BMS-204493 (RAR antagonist) |
5 µM |
2 d |
Stra8 expression not upregulated in germ cells, marker for failed initiation of meiosis |
|
|
Fetal ovaries in culture |
Mouse |
ATRA |
1 µM |
|
Acceleration of germ cells into meiosis, reduction in total number of germ cells |
|
|
Fetal ovaries in culture |
Mouse |
CD0336 (RARα agonist) |
1 nM |
|
Acceleration of germ cells into meiosis, reduction in total number of germ cells |
|
|
Naked oocytes, matured |
Camel |
ATRA |
20 µM |
24 h |
Stimulates meiosis and promotes oocyte viability |
|
|
Fetal ovaries in culture |
Chicken |
ATRA |
1 µM |
|
Stimulates meiotic initiation. |
Uncertainties and Inconsistencies
Mouse deletion models for the atRA synthesis enzymes Aldh1a1, Aldh1a2 and Aldh1a3 showed decreased expression of Stra8 in double (Aldh1a2/3) and triple (Aldh1a1/2/3) knockouts, although ultimately some germ cells were observed undergoing meiosis in these ovaries, suggesting that atRA is not essential for meiotic onset or progression(Chassot et al, 2020; Kumar et al, 2011). Similarly, transgenic mice lacking the three atRA nuclear receptors (RAR-α, -β, -γ) showed reduced levels of Stra8, although ultimately some germ cells were observed undergoing meiosis and were capable of producing live offspring (Vernet et al, 2020). Whether or not these models led to impaired fertility (such as sub-fertility) has not been elucidated and the size of their oocyte pools were not determined. In addition, the completeness of the genetic deletions in these models is not clear (discussed in (Spiller & Bowles, 2022)).
Gain of function mouse ovary models for CYP26A1 and CYP26B1 show that CYP26B1 can prevent oocytes from entering meiosis (as assessed by failure to induce Stra8 expression), whereas CYP26A1 does not have the same effect despite being a potent atRA degrading enzyme. This suggests that CYP26B1 works by additional mechanism(s) other than RA degradation (Bellutti et al, 2019).
Quantitative Understanding of the Linkage
The quantitative knowledge pertaining to this KER is very limited as little is known about 1) the levels of endogenous atRA produced in the ovaries in different mammals and 2) the levels of atRA required to achieve meiotic initiation.
Response-response relationshipIn vitro and ex vivo, it has been conclusively shown that low levels (as low as 1uM) of exogenous atRA can induce germ cells to enter meiosis in mice (Bowles et al, 2010) and rats (Livera et al, 2000) and, similarly, that it is necessary to achieve meiosis in in vitro-derived oocytes via primordial germ cells (PGCs)/PGC-like cells (PGCLCs) (Miyauchi et al, 2017). Yet, its exact role in vivo is under debate.
Whilst the relative levels of endogenous atRA produced by the ovary (for any species) remains unknown, similarly, the quantitative relationship between atRA levels and induction of meiosis also remains unclear. As such, the quantitative understanding of how much atRA needs to be reduced to prevent germ cells to enter meiosis in vivo is rated low.
Time-scaleThe time-scale for this KER is relatively short, limited to just a couple of days in e.g. mouse models. The induction of meiosis occurs shortly after the germ cells have colonized the ovary and occurs asynchronously (Bullejos & Koopman, 2004) (in mice this begins at E13.5 and is completed for all germ cells 2 days later at E15.5). Proliferation is halted and cells progress through leptonema, zygonema, pachynema, and arrest in diplonema of prophase I prior to birth (Zamboni, 1986). Time and duration of oogenesis varies between species, with rats the shortest duration of only 1-2 days, with other mammals such as pigs, cows, monkeys and humans lasting months (Peters, 1970).
The rat model of vitamin A deficiency (VAD) revealed severe defects to meiosis induction when Vitamin A was restricted/removed from the diet at E10.5, which is just 3 days prior to normal meiotic induction (Li & Clagett-Dame, 2009). Shorter time-frames have not been assessed to date, nor has rescue of VAD during later embryonic time-points been attempted.
Known modulating factorsNo modulating factors are currently known to alter the quantitative relationship between the two KEs.
Known Feedforward/Feedback loops influencing this KERDuring development, retinoic acid homeostasis is regulated by feedback loops, as both too much and too little RA can have deleterious effects on the embryo or fetus. The availability of atRA is regulated locally by maintaining a balance between synthesis (ALDH1 enzymes) and metabolism (CYP26 enzymes) (Kedishvili, 2013; Niederreither & Dollé, 2008; Roberts, 2020; Teletin et al, 2017).
The expression of Aldh1a2 and Cyp26a1 can act as part of a negative feedback loop in response to changes in RA levels. Exogenous atRA suppresses expression of Aldh1a2 (Niederreither et al, 1997) whereas blocking atRA signalling increases expression of Aldh1a2. Although Cyp26 expression does not require atRA, addition of atRA greatly increases the expression of Cyp26a1, and conversely, reduced levels of atRA reduces Cyp26a1 expression (de Roos et al, 1999; Hollemann et al, 1998; Ross & Zolfaghari, 2011; Sirbu et al, 2005). Negative feedback loops also extend to the enzymes that convert retinol to all-trans retinaldehyde as well as other related enzymes (Feng et al, 2010; Strate et al, 2009), including Ski, which seem to have cell-type specific roles (Melling et al, 2013; Niederreither & Dollé, 2008).
References
Bushue N, Wan YJY (2010) Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 62: 1285-1298
Ghyselinck NB, Duester G (2019) Retinoic acid signaling pathways. Development 146: dev167502
Spiller CM, Bowles J (2022) Instructing mouse germ cells to adopt a female fate. Sex Dev In Press
Relationship: 2481: Oocyte meiosis, disrupted leads to Ovarian follicle pool, reduced
AOPs Referencing Relationship
| AOP Name | Adjacency | Weight of Evidence | Quantitative Understanding |
|---|---|---|---|
| Inhibition of ALDH1A (RALDH) leading to impaired fertility via disrupted meiotic initiation of fetal oogonia of the ovary | adjacent | High | Moderate |
Evidence Supporting Applicability of this Relationship
| Life Stage | Evidence |
|---|---|
| Foetal | High |
| Sex | Evidence |
|---|---|
| Female | High |
Key Event Relationship Description
The establishment of the primordial follicle pool is a multistep process that spans from early fetal life to reproductive maturity. This period of time varies greatly between species, lasting only a few weeks in mice and rats, but years in humans (Tingen et al, 2009). One important process is for the mitotic primordial germs cells to enter meiosis prior to cyst formation (Findlay et al, 2015; Tingen et al, 2009). Notably, in females there is a massive loss of oocytes between cyst formation and time of maturity, and the exact mechanisms behind this oocyte degradation is not well understood (Findlay et al, 2015; Sun et al, 2017).
Evidence Supporting this KER
It is well established that disruption to meiosis during oocyte development can lead to sub-/infertility in females at reproductive age. There are numerous gene mutation in mice showing links between meiotic defects and fertility phenotypes, as well as associations to female fertility phenotypes in humans (Adelfalk et al, 2011).
Biological PlausibilityAlthough the entry into meiosis is required for oocyte development, the relationship between meiotic entry and final oocyte reserve remains unclear. However, there are strong correlations between disrupted meiosis and infertility (or aneuploidy) in females (Handel & Schimenti, 2010). For instance, in mice, ablation of Stra8 prevents oocytes from entering meiosis in the fetal ovaries and mature females are infertile (Baltus et al, 2006; Zhou et al, 2008). Mutation in Atm, a gene involved in recombination during meiosis, results in complete loss of primary oocytes in mice, and greatly reduced follicle pool in humans (Adelfalk et al, 2011; Agamanolis & Greenstein, 1979; Aguilar et al, 1968; Xu et al, 1996). Other examples include Fanca and Fancd2 genes that are involved in recombination. Mutations to these genes lead to oocyte degeneration and subfertility in mice (Cheng et al, 2000; Houghtaling et al, 2003; Wong et al, 2003).
Mice with Lhx8 ablation display total loss of oocytes. Lhx8-/- mice maintain oocytes during fetal development, but loose the oocytes shortly after birth by autophagy, likely because the oocytes have failed to enter meiosis in utero (Choi et al, 2008; D'Ignazio et al, 2018). Fzr1 is a regulator of mitotic cell division. When conditionally ablated from the germ cells, female mice display premature ovarian failure by 5 months of age and are subfertile; oocytes are lost in utero during early meiotic prophase I (Holt et al, 2014).
CYP51 (lanosterol 14 α-demethylase) is expressed by fetal oocytes and is involved in meiotic regulation (Mu et al, 2018). Inhibition of CYP51 activity reduces the formation of primordial follicles (Zhang et al, 2009) by disrupting entry into diplotene stage (Mu et al, 2018). Importantly, retinoic acid induces nuclear translocation of CYP51 in oocytes at the onset of meiosis (Mu et al, 2018).
Empirical Evidence
|
Study type |
Species |
Compound |
Effect Dose |
Duration |
Results |
Reference |
|
In vivo |
Mouse |
di(2-ethylhexyl) phthalate (DEHP) |
|
|
Delayed meiotic progression at 17.5 dpc (reduced Stra8 expression at time of initiation, 13.5 dpc) |
|
|
In vivo |
Mouse |
Bisphenol A (BPA) |
0.08 mg/kg/d |
12.5-17.5 dpc |
Delayed meiotic progression at 17.5 dpc (incl. decreased Stra8 expression) |
|
|
In vivo |
Mouse |
Paracetamol |
350 mg/kg/d |
13.5-21.5 dpc |
Delayed meiotic entry and reduced fertility |
|
|
In vivo |
Mouse |
Indomethacin |
0.8 mg/kg/d |
15.5-18.5 dpc |
Delayed meiotic entry and reduced fertility |
|
|
fetal ovary culture |
Mouse |
RS21745 (CYP51 inhibitor) |
10 µM |
3 days |
Oocytes arrest at zygote stage (delayed meiotic progression). |
|
|
fetal ovary culture |
Mouse |
RS21745 (CYP51 inhibitor) |
1, 25, 50 µM |
2 days exposure + 5 days no exposure |
Dose dependent reduction in follicle numbers; significant in 25 and 50 µM groups |
Quantitative Understanding of the Linkage
The quantitative understanding of this KER remains poorly understood, not least because the quantification of actual oocyte numbers at various stages of development are very difficult perform.
Response-response relationshipThe ovarian follicle pool (ovarian reserve) refers to the final number of primordial follicles in the mature ovary and is established through a series of events. In most mammals, it is determined during gestation or just after birth and relies on i) how many germ cells were established during embryogenesis, ii) their proliferation during migration and early ovary development, iii) death rate during oogenesis and iv) formation of primordial follicles at nest breakdown (Findlay et al, 2015). The last two stages, which includes nest formation and breakdown, is largely influenced by the mitotic-meiotic transition, in that oocytes that have failed to enter meiosis may contribute to the cysts population, but only high quality oocytes in meiotic prophase are spared during cyst breakdown (Findlay et al, 2015). Thus, there is a response-response relationship between meiotic entry and final follicle pool, albeit the quantitative relationship is not that well understood.
Time-scaleThe time-scale for oocyte mitotic-meiotic transition and subsequent nest breakdown varies between species, but generally takes place from mid gestation to around the time of birth. In mice, meiosis and nest formation is initiated from around E13, whereas in humans it initiates at around GW12-14 (Childs et al, 2012; Findlay et al, 2015; Grive & Freiman, 2015; Pepling, 2006; Tingen et al, 2009). Nest breakdown starts just before birth in mice and completes around postnatal day 5 (Grive & Freiman, 2015; Pepling, 2006). In humans, nest breakdown takes place during second trimester (Grive & Freiman, 2015; Tingen et al, 2009).
Known modulating factorsatRA is synthesized from vitamin A in a two-step enzymatic pathway. Vitamin A is required from the diet; hence, dietary changes to vitamin A can greatly affect the level of available atRA and thus modulate atRA-regulated responses.
References
Relationship: 2525: Ovarian follicle pool, reduced leads to irregularities, ovarian cycle
AOPs Referencing Relationship
| AOP Name | Adjacency | Weight of Evidence | Quantitative Understanding |
|---|---|---|---|
| Inhibition of ALDH1A (RALDH) leading to impaired fertility via disrupted meiotic initiation of fetal oogonia of the ovary | adjacent | Moderate | Low |
Evidence Supporting Applicability of this Relationship
| Term | Scientific Term | Evidence | Links |
|---|---|---|---|
| human, mouse, rat | human, mouse, rat | High | NCBI |
| Life Stage | Evidence |
|---|---|
| Adult, reproductively mature | High |
| Sex | Evidence |
|---|---|
| Female | High |
Key Event Relationship Description
Reduced ovarian reserve, meaning the finite pool of primordial follicles containing the immature oocytes, is leading to ovarian cycle irregularities. Cycle irregularities include disturbances of the ovarian cycle like shorter cycle and prolonged estrus and/or ovulation problems like deferred ovulation and anovulation. This KER is considered canonical information.
Evidence Supporting this KER
Biological PlausibilityAll primordial follicles are formed during early development (fetal period in humans, perinatally in rodents) and can stay dormant for long periods of time (years in humans, months in rodents). The stock of primordial dormant follicles constitutes the ‘ovarian reserve’. In humans, millions of follicles are formed by mid-gestation (Wallace & Kelsey, 2010). Upon puberty, the hypothalamus-pituitary-ovary (HPO) axis matures enabling the primordial follicles to grow into maturity in a process called folliculogenesis, which serves two functions: i) secretion of steroid hormones that enable pregnancy, and ii) production of mature oocytes that are ovulated for possible fertilization.
Cohorts of primordial follicles continuously enter the growing pool. After puberty, growing antral follicles are recruited for final maturation during each menstrual cycle (estrus cycle in rodents) by gonadotropins secreted from the pituitary gland but only a limited number will reach maturity and ovulate oocytes (typically one in humans and 10-20 in rodents). The majority of follicles never reach maturity and instead die in a process called atresia. Therefore, the ovarian reserve is irreversibly depleted with age. When the reserve is depleted to a level that cannot faithfully maintain steroid production, fertility ceases. In humans, fertility ends in sterility at menopause when less than 1,000 follicles remain (Wallace & Kelsey, 2010).
Regular cycles are considered as an indicator of reproductive health and often used in animal studies as the earliest biomarker to reflect disruption of fertility and ovotoxicity (Hooser et al, 1994). OECD test guidelines 407, 416 and 443 include rodent cyclicity as an endpoint to assess reproductive toxicity (OECD, 2001; OECD, 2008; OECD, 2018). In humans, normal menstrual cycle lasts 28-35 days, and in rodents 4-6 days. When the ovarian reserve is depleted to a critically low level, like naturally during the perimenopausal period in humans, the variability of the cycle length increases with many of the cycles being anovulatory. The lower the ovarian reserve is, the lower the probability of growing follicles to exist at any given time point. Since the growing follicles produce steroid hormones that are essential for cyclicity, the lack of growing follicles leads to disturbances of the HPO axis. Therefore, the lower the ovarian reserve is, the less probable are regular cycles; reflected by regular menstruation in humans (O'Connor et al, 1998; O'Connor et al, 2001).
Supporting evidence exists. Anti-Müllerian hormone (AMH) is a growth factor secreted by growing follicles. Low levels of AMH correlate with longer cycle length (Harris et al, 2021). Other studies have connected AMH or antral follicle count (AFC), another ovarian reserve marker, to shorter cycles (Younis et al, 2020). A systematic review and meta-analysis have revealed in regularly cycling women, a shorter cycle is associated with lower ovarian reserve based on AMH or AFC (Younis et al, 2020). Young women diagnosed with premature ovarian failure have also reported shorter cycles (Guzel et al, 2017). In addition, it is well established in humans that diminishing ovarian reserve leads to perimenopause (a period or irregular cycles) and eventually menopause (complete cessation of cycles).
Empirical EvidenceStressors that are known to deplete the ovarian reserve include cancer treatments, which kill primordial follicles and disrupt folliculogenesis. Alkylating chemotherapy agents like cyclophosphamide and cisplatin are highly ovotoxic, as well as radiation therapy towards ovaries (Pampanini et al, 2020). Therapies based on high dose alkylators and radiation towards ovaries lead with high likelihood to amenorrhea, infertility and premature ovarian insufficiency in humans due to depletion of ovarian reserve and therefore constitute an indication for clinical fertility preservation (ESHRE_Guideline_Group_on_Female_Fertility_Preservation et al, 2020; Pampanini et al, 2020).
In mice, it has been shown that cisplatin induces primordial follicle loss in a dose-depended manner (Meirow et al, 1999). Cyclophosphamide can accelerate primordial follicle loss in mice and in human ovarian tissue (Kalich-Philosoph et al., 2013; Lande et al., 2017). In human xenografts in mice, the same compound decreased the primordial follicle density(Oktem & Oktay, 2007). These key studies indicate the effect of chemotherapy compounds on the size of the ovarian reserve (Meirow et al, 2010). In treated patients, although there is often no direct information on the size of the ovarian reserve, a rapid decrease of AMH levels has been observed following high risk chemotherapy. Patients receiving chemotherapy have also been shown to have an increased risk of premature ovarian failure. In addition, some studies have shown that the number of healthy follicles is significantly decreased and that of atretic follicles increased in human ovarian tissue following alkylating chemotherapy (Pampanini et al, 2019). These data establish a clear indication of diminished ovarian reserve following chemotherapy. Importantly, chemotherapy compounds also affect the menstrual cycle, with patients experiencing amenorrhea and irregular cycles (Jacobson et al., 2016; Meirow et al., 2010).
Another stressor known to affect the ovarian reserve is smoking. Cigarette smoke contains thousands of chemicals, several of which have been shown to be ovotoxic (Budani & Tiboni, 2017). Mice exposed in vivo to cigarette smoke have significantly fewer primordial follicles compared to the control group (Tuttle et al., 2009). Smoking women display reduced ovarian reserve markers and experience irregular cycles compared to non-smokers of the same age group (El-Nemr et al, 1998; Sharara et al, 1994).
Additional chemical insults affecting the ovarian reserve and causing menstrual cycle irregularities are presented in Table 1. These studies in animal models demonstrate how these chemicals directly target primordial follicles and cause menstrual cycle irregularities. Vinylcyclohexene diepoxide (VCD), metabolite of 4-vinylcyclohexene (VCH), is the most commonly used chemical in these studies and is often used to induce reproductive senescence in model organisms.
Table 1: In vivo studies demonstrating that effects on the KE upstream affect the KE downstream. VCD: vinylcyclohexene diepoxide, VCH: 4-vinylcyclohexene, BPA: bisphenol A, DEHP: bis(2-ethylhexyl) phthalate, B[a]P: Benzo[a]pyrene
|
Species |
Compound |
Dose |
Duration |
Reduced Ovarian Reserve |
Ovarian Cycle Irregularities |
Reference |
|
Mouse |
VCD |
160 mg/kg/day
|
15 days |
No primordial follicles at the end of exposure |
All treated animals exhibited irregular cycles by day 58
|
|
|
Mouse |
VCD |
160 mg/kg/day
|
15 days |
No follicles on day 156 |
Longer cycles after day 28 |
|
|
Rat |
VCD |
80 mg/kg/day |
30 days |
Reduced number of primordial and primary follicles at the end of exposure
|
Longer cycles by day 360 |
|
|
Mouse |
VCD |
160 mg/kg/day |
10 days 20 days |
Reduced number of primordial and primary follicles by the end of 10-day exposure, all follicles reduced by the end of the 20-day exposure
|
Longer cycles on 135.1 ± 6.9 days for 10-day exposure and on 52.0 ± 2.2 days for 20-day exposure |
|
|
Rat |
VCD |
80 mg/kg/day |
30 days |
Reduced number of primordial and primary follicles at the end of exposure
|
Irregular cycles of adult but not immature rats within the 30-day exposure |
|
|
Mouse |
VCH |
800 mg/kg/day |
30 days |
Reduced number of all follicles on day 30 – primordial and primary more affected, no follicles at day 360
|
Acyclicity by day 360 |
|
|
Mouse |
BPA |
10, 100 μg/kg/day 1, 10 mg/kg/day
|
28 days |
Reduced number of primordial follicles at the end of exposure
|
Longer cycles |
|
|
Mouse |
DEHP |
20, 200 mg/kg/day
|
10 days |
Reduced number of primordial follicles at the end of exposure
|
Longer cycles within the 10-day exposure |
|
|
Rat |
B[a]P, DEHP, B[a]P + DEHP
|
10 mg/kg/day B[a]P 600 mg/kg/day DEHP
|
60 days (on alternate days) |
Reduced number of primordial follicles at the end of exposure |
Longer cycles within the 60-day exposure |
Uncertainties and Inconsistencies
As mentioned, several chemotherapy agents damage ovarian reserve and disrupt folliculogenesis. However, it has been shown that regular menses can resume upon treatment cessation (Jacobson et al, 2016). Therefore, in this case reduced ovarian reserve did not lead to permanent irregularities of ovarian cycle. In a systematic review and meta-analysis investigating the connection between the ovarian reserve and the length of the menstrual cycle, studies are mentioned where reduced ovarian reserve markers did not associate with irregular menstrual cycles (Younis et al, 2020). Several factors affect the impact of chemotherapy on ovarian health in humans, including the age at the treatment, size of ovarian reserve at treatment, and treatment regimen. However, late side effects of chemotherapy often include amenorrhea, premature ovarian insufficiency, and infertility.
Menstrual irregularities can be caused by factors other than reduced ovarian reserve. The most common factor affecting cyclicity is HPO axis dysregulation causing hypothalamic amenorrhea (Berga & Naftolin, 2012). Another example is the contraceptive pill that decreases gonadotropin secretion by the pituitary gland, leading to inhibition of folliculogenesis and amenorrhea. Changes in hormone levels produced by the pituitary gland have also been connected to shorter and anovulatory cycles (Mumford et al., 2012). Another factor affecting cyclicity is the thyroid gland function. Thyroid function disturbances, like hypo and hyperthyroidism have been connected to menstrual disturbances (Koutras, 1997).
Quantitative Understanding of the Linkage
poor
Time-scaleThe timescale at which disruption in cyclicity occurs depends on the type of follicles that are affected, size of the reserve at the time of insult, and the extent of the damage. When a stressor targets selectively the ovarian reserve, it might take months (or years in humans) for the disruptions in cyclicity to be observed (Hoyer & Sipes, 1996). This delay was evident in some of the animal studies mentioned in Table 1 (Hooser et al., 1994; Lohff et al., 2006; Mayer et al., 2002).
Known modulating factors
The size of the ovarian reserve at the time of stressor exposure is a factor that can affect the response-response relationship of this KER. Therefore, age can also be a modulating factor, as observed in the animal study mentioned in table 1, where even though all treated rats exhibited reduction in the ovarian reserve, irregular cycles were only observed in the adult ones but not the immature ones (Flaws et al., 1994). In addition, chemotherapy effects on fertility tend to be more severe with increasing age due to a smaller ovarian reserve (Jacobson et al, 2016).
Changes in hormones can affect menstrual/estrus cyclicity, without being connected to the size of the ovarian reserve. For instance, experiencing stress has been shown to affect the hypothalamus-pituitary-adrenal axis (HPA) activity. A high body mass index (BMI) has been shown to affect sex hormone-binding globulin (SHBG), free androgen index (FAI), testosterone, and insulin levels. Smoking, although it can also affect the reserve, can cause hypoestrogenism. Therefore, stress, obesity and smoking can affect menstrual cyclicity and influence the response-response relationship of this KER (Bae et al, 2018).
Known Feedforward/Feedback loops influencing this KERHPO axis regulates estrus/menstrual cycle, and is based on positive and negative feedback loops by ovarian steroids and peptide hormones, and hormones released by the hypothalamus and pituitary gland.
References
Berga S, Naftolin F (2012) Neuroendocrine control of ovulation. Gynecol Endocrinol 28 Suppl 1: 9-13
Kalich-Philosoph, L., Roness, H., Carmely, A., Fishel-Bartal, M., Ligumsky, H., Paglin, S., Wolf, I., Kanety, H., Sredni, B., & Meirow, D. (2013). Cyclophosphamide triggers follicle activation and "burnout "; AS101 prevents follicle loss and preserves fertility. Science Translational Medicine, 5(185).
Koutras, D. A. (1997). Disturbances of menstruation in thyroid disease. Annals of the New York Academy of Sciences, 816, 280–284.
Lande, Y., Fisch, B., Tsur, A., Farhi, J., Prag-Rosenberg, R., Ben-Haroush, A., Kessler-Icekson, G., Zahalka, M. A., Ludeman, S. M., & Abir, R. (2017). Short-term exposure of human ovarian follicles to cyclophosphamide metabolites seems to promote follicular activation in vitro. Reproductive BioMedicine Online, 34(1), 104–114.
Mumford, S. L., Steiner, A. Z., Pollack, A. Z., Perkins, N. J., Filiberto, A. C., Albert, P. S., Mattison, D. R., Wactawski-Wende, J., & Schisterman, E. F. (2012). The utility of menstrual cycle length as an indicator of cumulative hormonal exposure. Journal of Clinical Endocrinology and Metabolism, 97(10).
Relationship: 394: irregularities, ovarian cycle leads to impaired, Fertility
AOPs Referencing Relationship
| AOP Name | Adjacency | Weight of Evidence | Quantitative Understanding |
|---|---|---|---|
| Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | non-adjacent | Moderate | |
| Inhibition of ALDH1A (RALDH) leading to impaired fertility via disrupted meiotic initiation of fetal oogonia of the ovary | adjacent | High | Low |
| Androgen receptor (AR) antagonism leading to decreased fertility in females | adjacent | High | Low |
Evidence Supporting Applicability of this Relationship
In many instances, human female reproductive toxicity of an agent is suspected based on studies performed in experimental animals. The neuroendocrinology, steroid biochemistry, and other physiologic events in the females of most small experimental species often used (mouse, rat, hamster) are similar in their susceptibility to disruption by toxicants (Massaro, 1997).
Although the assessment of the human ovarian cycle may have a variety of biomarkers distinct from those in rats, many of the underlying endocrine mechanisms associated with successful follicular development, ovulation, pregnancy, and parturition are homologous between the two (for review see (Bretveld et al., 2006). For this reason, a toxicant-induced perturbation of ovarian cycles in female rats suggest that a compound may function as a reproductive toxicant in human females.
Mice
- environmental air pollution (Mohallem et al., 2005)
- phthalates (DEHP)
- abortion rate of 100% in F0 dams in the 500-mg/kg/day was observed, in F1 females found that the total number of F2 embryos (exposed to DEHP only as germ cells) was not impaired. However, in the 0.05- and 5-mg DEHP groups, 28% and 29%, respectively, of the blastocysts were degenerated, compared with 8% of controls (Schmidt et al., 2012).
- Lamb et al. studied fertility effects of DEHP in mice (both sexes) and found that DEHP caused dose-dependent decreases in fertility. DBP exposure resulted in a reduction in the numbers of litters per pair and of live pups per litter and in the proportion of pups born alive at the 1.0% amount, but not at lower dose levels. A crossover mating trial demonstrated that female mice, but not males, were affected by DBP, as shown by significant decreases in the percentage of fertile pairs, the number of live pups per litter, the proportion of pups born alive, and live pup weight. DHP in the diet resulted in dose-related adverse effects on the numbers of litters per pair and of live pups per litter and proportion of pups born alive at 0.3, 0.6, and 1.2% DHP in the diet. A crossover mating study demonstrated that both sexes were affected. DEHP (at 0.1 and 0.3%) caused dose-dependent decreases in fertility and in the number and the proportion of pups born alive. A crossover mating trial showed that both sexes were affected by exposure to DEHP. These data demonstrate the ability of the continuous breeding protocol to discriminate the qualitative and quantitative reproductive effects of the more and less active congeners as well as the large differences in reproductive toxicity attributable to subtle changes in the alkyl substitution of phthalate esters (Lamb et al., 1987).
Rat phthalates (DEHP)
- female rats exposed to a high dose of DEHP (3,000 mg/kg/day) had irregular estrous cycles and a slight decline in pregnancy rate (Takai et al., 2009). At 1,000 mg/kg bw/day over a period of 4 weeks did not disturb female fertility or early embryo development.
- There was significant evidence that 5, 15, 50, and 400 mg /kg/day females differed from the control females in the relative amount of time spent in oestrous stages, however no changes were revealed in the number of females with regular cycles, cycle length, number of cycles, and in number of cycling females across the dose groups as compared to the control females The litter size (number of live pups) produced by the P0 generation was significantly reduced in the 400 mg/kg/day dose group (Blystone et al., 2010).
Human
Studies showing a correlation between decreased fertility and;
- professional activity (Olsen, 1994)
- phthalates (DEHP) In occupationally exposed women to high concentration of phthalates exhibit hypoestrogenic anovulary cycles and was associated with decreased pregnancy rate and higher miscarriage rates (Aldyreva,M.V.,Klimove,T.S.,Iziumova,A.S.,Timofeevskaia,L.A., 1975).
- smoking (Hull, North, Taylor, Farrow, & Ford, 2000)
- the use of certain drugs or radiation exposure (Dobson & Felton, 1983)
For the taxonomic applicability see also the Table 1.
Key Event Relationship Description
The ovarian cycle irregularities impact on reproductive capacity of the females that may result in impaired fertility:
1. Irregular cycles may reflect impaired ovulation. Extended vaginal estrus usually indicates that the female cannot spontaneously achieve the ovulatory surge of LH (Huang and Meites, 1975). The persistence of regular vaginal cycles after treatment does not necessarily indicate that ovulation occurred, because luteal tissue may form in follicles that have not ruptured. However, that effect should be reflected in reduced fertility. Conversely, subtle alterations of cyclicity can occur at doses below those that alter fertility (Gray et al., 1989).
2. Persistent or constant vaginal cornification (or vaginal estrus) may result from one or several effects. Typically, in the adult, if the vaginal epithelium becomes cornified and remains so in response to toxicant exposure, it is the result of the agent’s estrogenic properties (i.e., DES or methoxychlor), or the ability of the agent to block ovulation. In the latter case, the follicle persists and endogenous estrogen levels bring about the persistent vaginal cornification. Histologically, the ovaries in persistent estrus will be atrophied following exposure to estrogenic substances. In contrast, the ovaries of females in which ovulation has been blocked because of altered gonadotropin secretion will contain several large follicles and no corpora lutea. Females in constant estrus may be sexually receptive regardless of the mechanism responsible for this altered ovarian condition. However, if ovulation has been blocked by the treatment, an LH surge may be induced by mating (Brown-Grant et al., 1973; Smith, E.R. and Davidson, 1974) and a pregnancy or pseudopregnancy may ensue. The fertility of such matings is reduced (Cooper et al., 1994).
3. Significant delays in ovulation can result in increased embryonic abnormalities and pregnancy loss (Fugo and Butcher, 1966; Cooper et al., 1994).
4. Persistent diestrus indicates temporary or permanent cessation of follicular development and ovulation, and thus at least temporary infertility.
5. Prolonged vaginal diestrus, or anestrus, may be indicative of agents (e.g., polyaromatic hydrocarbons) that interfere with follicular development or deplete the pool of primordial follicles (Mattison and Nightingale, 1980) or agents such as atrazine that interrupt gonadotropin support of the ovary (Cooper et al., 1996). Pseudopregnancy is another altered endocrine state reflected by persistent diestrus. The ovaries of anestrous females are atrophic, with few primary follicles and an unstimulated uterus (Huang and Meites, 1975). Serum estradiol and progesterone are abnormally low.
6. Lengthening of the cycle may be a result of increased duration of either estrus or diestrus.
Evidence Supporting this KER
Biological PlausibilityIn females, normal reproductive function involves the appropriate interaction of central nervous system, anterior pituitary, oviducts, uterus, cervix and ovaries. During the reproductive years the ovary is the central organ in this axis. The functional unit within the ovary is the follicle which is composed of theca; granulosa cells and the oocyte. The somatic compartment synthesizes and secrets hormones (steroids and growth factors) necessary for the orchestration of the inter-relationship between the other parts of the reproductive tract and the central nervous system. Oestrus cycle is under strict hormonal control, therefore perturbations of hormonal balance lead to perturbations of normal cyclicity (change in number of cycles or duration of each phase) and/or ovulation problems leading to impaired female reproductive function. However, there are other mechanisms that might result in impaired fertility (e.g cellular maturation in ovary).
Empirical EvidenceMany chemicals are found to interfere with reproductive function in the female. This interference is commonly expressed as a change in normal morphology of the reproductive tract or in ovarian cycle irregularities (disturbance in the duration of particular phases of the estrous cycle and/or ovulation problems). Monitoring estrous cyclicity provides a means to identify alterations in reproductive functions which are mediated through nonestrogenic as well as estrogenic mechanisms (Blasberg, Langan, & Clark, 1997), (Clark, Blasberg, & Brandling-Bennett, 1998). Adverse alteration in the nonpregnant female reproductive system have been observed at dose levels below those that result in reduced fertility or produce other overt effects on pregnancy or pregnancy outcomes. A disruption of cycling caused by xenobiotic treatment can induce a persistent estrus, a persistent diestrus, an irregular pattern with cycles of extended duration and ovulation problems. Common classes of chemicals have been shown to cause cycle irregularities in rats, humans, and non-human primates. Examples include the polychlorinated biphenyls (PCBs) and dioxins, which are associated with such irregularities in rats and humans (e.g (Li, Johnson, & Rozman, 1995) (Meerts et al., 2004), (Chao, Wang, Lin, Lee, & Päpke, 2007) and various agricultural pesticides, including herbicides, fungicides, and fumigants for review see (Bhattacharya & Keating, 2012),(Bretveld, Thomas, Scheepers, Zielhuis, & Roeleveld, 2006).
|
Compound class |
Species |
AO:ovarian cycle irregularities |
AO:Impaired fertility |
reference |
|
Phthalates (DEHP) |
rat |
5-400 mg/kg/day females differed from the control in the relative amount of time spent in oestrous stages |
number of live pups (P0) reduced (400 mg/kg/day) |
(Blystone et al., 2010) |
|
Phthalates (DEHP) |
rat |
irregular estrous cycles (3,000 mg/kg/day) |
slight decline in pregnancy rate (3,000 mg/kg/day) |
(Takai et al., 2009) |
|
Phthalates (DEHP) |
mice |
|
dose-dependent decreases in fertility |
(Lamb, Chapin, Teague, Lawton, & Reel, 1987) |
|
Phthalates (DEHP) |
mice |
No change |
abortion rate of 100% in F0 dams (500-mg/kg/day) |
(Schmidt, Schaedlich, Fiandanese, Pocar, & Fischer, 2012). |
|
Phthalates (DEHP) |
sheep |
dose-dependent effect on the duration of the estrous cycles shortening of the ovulatory cycles due mainly to a reduction in the size and lifespan of CL |
|
(Herreros, Gonzalez-Bulnes, et al., 2013) |
|
Phthalates (DEHP) |
sheep |
No effect on ovulatory efficiency |
|
(Herreros, Encinas, et al., 2013) |
|
Phthalates (DEHP) |
rat |
No changes in F0, increase of cycle by 0.4 day in F1 at 10,000ppm |
18% and 21% decrease in live pups/litter F0 at 7500ppm and 10,000ppm respectively, no viable litters (F1 10,000 ppm ~643.95mg/kg/day) |
(NTP, 2005) |
|
Phthalates (DEHP) |
rat |
Deficit in growing follicles and corpora lutea |
4-fold increase in females with stillborn pups in F0 at 9000ppm 2.1-fold Postimplantation loss in F0 at 9000ppm |
(Schilling, K., Deckardt. K., Gembardt, Chr., and Hildebrand, 1999) |
|
Phthalates (DEHP) |
rat |
prolong the estrous cycle, anovulation |
|
(Davis, Maronpot, & Heindel, 1994) |
|
Phthalates |
|
|
Reduced fertility and fecundity |
(Wolf et al., 1999) |
|
Organochlorine (methoxychlor) |
rat |
Decreased number of cycles, extended diestrus and estrus |
|
(Laws, 2000) |
|
Organotins tributyltin chloride (TBTCl) |
rat |
At 125 ppm vaginal opening and impaired estrous cyclicity |
|
(Ogata et al., 2001) |
Table 1 Summary the empirical evidence supporting the KER.
It is known that exposure to 17-β-estradiol can disrupt the normal 4- to 5-day estrous cycle in adult female rats by inducing an extended period of diestrus consistent with pseudopregnancy within 5–7 days after the exposure (Gilmore & McDonald, 1969). This is due to the estrogen-dependent increase in prolactin that rescues ovarian corpora lutea and the subsequent synthesis and release of progesterone (Cooper, R. L., and Goldman, 1999). Significant evidence that the estrous cycle (or menstrual cycle in primates) has been disrupted should be considered an adverse effect (OECD, 2008).
Uncertainties and InconsistenciesChemicals may be found to interfere with reproductive function in the female. This interference is commonly expressed as a change in normal morphology of the reproductive tract or a disturbance in the duration of particular phases of the estrous cycle. However, menstrual cyclicity is affected by many parameters such as age, nutritional status, stress, exercise level, certain drugs, and the use of contraceptive measures that alter endocrine feedback. In nonpregnant females, repetitive occurrence of the four stages of the estrous cycle at regular, normal intervals suggests that neuroendocrine control of the cycle and ovarian responses to that control are normal. Even normal, control animals can show irregular cycles. However, a significant alteration compared with controls in the interval between occurrence of estrus for a treatment group is cause for concern. Generally, the cycle will be lengthened or the animals will become acyclic. Therefore changes in cyclicity should be interpreted with caution and not judged adverse without a comprehensive consideration of additional relevant endpoints in a weight-of-evidence approach.
Inconsistencies
Two generation studies by Tyl et al with Butyl benzyl phthalate (BBP) did not observe effects in F0 females on any parameters of estrous cycling, mating, or gestation. However, F1 females carrying F2 litters at and reduced number of total and live pups/litter at birth, with no effects on pre- or postnatal survival (Tyl et al., 2004).
References
Aldyreva,M.V.,Klimove,T.S.,Iziumova,A.S.,Timofeevskaia,L.A. (1975). The effect of phthalate plasticizers on the generative function. Gig.Tr.Prof.Zabol., (19), 25–29.
Bhattacharya, P., & Keating, A. F. (2012). Impact of environmental exposures on ovarian function and role of xenobiotic metabolism during ovotoxicity. Toxicology and Applied Pharmacology, 261(3), 227–35. doi:10.1016/j.taap.2012.04.009
Blasberg, M. E., Langan, C. J., & Clark, A. S. (1997). The effects of 17 alpha-methyltestosterone, methandrostenolone, and nandrolone decanoate on the rat estrous cycle. Physiology & Behavior, 61(2), 265–72.
Blystone, C. R., Kissling, G. E., Bishop, J. B., Chapin, R. E., Wolfe, G. W., & Foster, P. M. D. (2010). Determination of the di-(2-ethylhexyl) phthalate NOAEL for reproductive development in the rat: importance of the retention of extra animals to adulthood. Toxicological Sciences : An Official Journal of the Society of Toxicology, 116(2), 640–6. doi:10.1093/toxsci/kfq147
Bretveld, R. W., Thomas, C. M. G., Scheepers, P. T. J., Zielhuis, G. A., & Roeleveld, N. (2006). Pesticide exposure: the hormonal function of the female reproductive system disrupted? Reproductive Biology and Endocrinology : RB&E, 4(1), 30. doi:10.1186/1477-7827-4-30
Chao, H.-R., Wang, S.-L., Lin, L.-Y., Lee, W.-J., & Päpke, O. (2007). Placental transfer of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls in Taiwanese mothers in relation to menstrual cycle characteristics. Food and Chemical Toxicology : An International Journal Published for the British Industrial Biological Research Association, 45(2), 259–65. doi:10.1016/j.fct.2006.07.032
Clark, A. S., Blasberg, M. E., & Brandling-Bennett, E. M. (1998). Stanozolol, oxymetholone, and testosterone cypionate effects on the rat estrous cycle. Physiology & Behavior, 63(2), 287–95.
Cooper, R. L., and Goldman, J. M. (1999). Vaginal cytology. In An Evaluation and Interpretation of Reproductive Endpoints for Human Health Risk Assessment. Washington. Davis, B. J., Maronpot, R. R., & Heindel, J. J. (1994). Di-(2-ethylhexyl) phthalate suppresses estradiol and ovulation in cycling rats. Toxicology and Applied Pharmacology, 128(2), 216–23. doi:10.1006/taap.1994.1200
Dobson, R. L., & Felton, J. S. (1983). Female germ cell loss from radiation and chemical exposures. American Journal of Industrial Medicine, 4(1-2), 175–90.
Gilmore, D. P., & McDonald, P. G. (1969). Induction of prolonged diestrus in the rat by a low level of estrogen. Endocrinology, 85(5), 946–8. doi:10.1210/endo-85-5-946 Herreros, M. A., Encinas, T., Torres-Rovira, L., Garcia-Fernandez, R. A., Flores, J. M., Ros, J. M., & Gonzalez-Bulnes, A. (2013). Exposure to the endocrine disruptor di(2-ethylhexyl)phthalate affects female reproductive features by altering pulsatile LH secretion. Environmental Toxicology and Pharmacology, 36(3), 1141–9. doi:10.1016/j.etap.2013.09.020
Herreros, M. A., Gonzalez-Bulnes, A., Iñigo-Nuñez, S., Contreras-Solis, I., Ros, J. M., & Encinas, T. (2013). Toxicokinetics of di(2-ethylhexyl) phthalate (DEHP) and its effects on luteal function in sheep. Reproductive Biology, 13(1), 66–74. doi:10.1016/j.repbio.2013.01.177
Hull, M. G., North, K., Taylor, H., Farrow, A., & Ford, W. C. (2000). Delayed conception and active and passive smoking. The Avon Longitudinal Study of Pregnancy and Childhood Study Team. Fertility and Sterility, 74(4), 725–33.
Lamb, J. C., Chapin, R. E., Teague, J., Lawton, A. D., & Reel, J. R. (1987). Reproductive effects of four phthalic acid esters in the mouse. Toxicology and Applied Pharmacology, 88(2), 255–69.
Laws, S. C. (2000). Estrogenic Activity of Octylphenol, Nonylphenol, Bisphenol A and Methoxychlor in Rats. Toxicological Sciences, 54(1), 154–167. doi:10.1093/toxsci/54.1.154
Li, X., Johnson, D. C., & Rozman, K. K. (1995). Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on estrous cyclicity and ovulation in female Sprague-Dawley rats. Toxicology Letters, 78(3), 219–22.
Massaro, E. J. (Ed.). (1997). Handbook of Human Toxicology, Volume 236. Taylor & Francis.
Meerts, I. A. T. M., Hoving, S., van den Berg, J. H. J., Weijers, B. M., Swarts, H. J., van der Beek, E. M., … Brouwer, A. (2004). Effects of in utero exposure to 4-hydroxy-2,3,3’,4',5-pentachlorobiphenyl (4-OH-CB107) on developmental landmarks, steroid hormone levels, and female estrous cyclicity in rats. Toxicological Sciences : An Official Journal of the Society of Toxicology, 82(1), 259–67. doi:10.1093/toxsci/kfh251
Mohallem, S. V., de Araújo Lobo, D. J., Pesquero, C. R., Assunção, J. V., de Andre, P. A., Saldiva, P. H. N., & Dolhnikoff, M. (2005). Decreased fertility in mice exposed to environmental air pollution in the city of Sao Paulo. Environmental Research, 98(2), 196–202. doi:10.1016/j.envres.2004.08.007
NTP. (2005). Multigenerational Reproductive Assessment by Continuous Breeding when Diethylhexylphthalate (CAS 117-81-7).
OECD. (2008). No 43: Guidance document on mammalian reproductive toxicity testing and assessment.
Ogata, R., Omura, M., Shimasaki, Y., Kubo, K., Oshima, Y., Aou, S., & Inoue, N. (2001). Two-generation reproductive toxicity study of tributyltin chloride in female rats. Journal of Toxicology and Environmental Health. Part A, 63(2), 127–44. doi:10.1080/15287390151126469
Olsen, J. (1994). Is human fecundity declining--and does occupational exposures play a role in such a decline if it exists? Scandinavian Journal of Work, Environment & Health, 20 Spec No, 72–7.
Schilling, K., Deckardt. K., Gembardt, Chr., and Hildebrand, B. (1999). Di-2-ethylhexyl phthalate – two-generation reproduction toxicity range-finding study in Wistar rats. Continuos dietary administration.
Schmidt, J.-S., Schaedlich, K., Fiandanese, N., Pocar, P., & Fischer, B. (2012). Effects of di(2-ethylhexyl) phthalate (DEHP) on female fertility and adipogenesis in C3H/N mice. Environmental Health Perspectives, 120(8), 1123–9. doi:10.1289/ehp.1104016
Takai, R., Hayashi, S., Kiyokawa, J., Iwata, Y., Matsuo, S., Suzuki, M., … Deki, T. (2009). Collaborative work on evaluation of ovarian toxicity. 10) Two- or four-week repeated dose studies and fertility study of di-(2-ethylhexyl) phthalate (DEHP) in female rats. The Journal of Toxicological Sciences, 34 Suppl 1(I), SP111–9.
Tyl, R. W., Myers, C. B., Marr, M. C., Fail, P. a, Seely, J. C., Brine, D. R., … Butala, J. H. (2004). Reproductive toxicity evaluation of dietary butyl benzyl phthalate (BBP) in rats. Reproductive Toxicology (Elmsford, N.Y.), 18(2), 241–64. doi:10.1016/j.reprotox.2003.10.006
Wolf, C., Lambright, C., Mann, P., Price, M., Cooper, R. L., Ostby, J., & Gray, L. E. (1999). Administration of potentially antiandrogenic pesticides (procymidone, linuron, iprodione, chlozolinate, p,p’-DDE, and ketoconazole) and toxic substances (dibutyl- and diethylhexyl phthalate, PCB 169, and ethane dimethane sulphonate) during sexual differen. Toxicology and Industrial Health, 15(1-2), 94–118. doi:10.1177/074823379901500109